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ABSTRACT 
The mechanisms by which mutations in the gene encoding superoxide 
dismutase 1 (S0D1) lead to amyotrophic lateral sclerosis (ALS) remain 
incompletely understood. Mutant S0D1 inclusions are observed in both ALS 
patients and animal models of the disease. Chaperone proteins have been 
shown to reduce mutant S0D1 inclusion formation in both cell and animal 
systems and, up-regulation of heat shock proteins (HSPs) in a mouse model of 
ALS increases their life expectancy. The results presented in this thesis are 
based on an investigation into the role of small heat shock proteins (sHSPs) in 
mutant S0D1 inclusion formation, using a model HEK293 cell system. 
Over-expression of yellow fluorescent protein (YFP)-tagged G85R 
mutant S0D1 in HEK293 cells and subsequent treatment with proteasome 
inhibitor leads to mutant S0D1-inclusion formation, as shown by 
immunofluorescence (IMF) microscopy. Using this model of mutant S0D1-
inclusion formation, we demonstrate that over-expression of sHSPs decreases 
the proportion of insoluble mutant S0D1 present within these cells. Mutations in 
these sHSPs prevent this function, and further increase the proportion of 
insoluble mutant SODI. These mutant sHSPs also cause an increase in the 
insolubility of normally soluble proteins, such as wild-type S0D1. Similar results 
were observed in Neuro 2a cells, where over-expression of sHSPs caused the 
phenotype of the mutant SODI inclusions to change, from dense, tight 
structures to more diffuse ones. 
We have shown that sHSPs decrease the amount of insoluble mutant 
SODI in HEK293 cells, supporting reports that chaperone proteins prevent 
mutant S0Đ1ฟnclusioñ formation and are ben๙ 
Whether the clinical use of these proteins will be of therapeutic benefit in the 
treatment of ALS patients remains to be determined. 
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ABBREVIATIONS 
ALLN - N-Acetyl-Leu-Leu-Nle-CHO 
ALS - amyotrophic lateral sclerosis 
APP - ß-amyloid precursor protein 
ATP - adenosine triphosphate 
BSA - bovine serum albumin 
CCS 一 copper chaperone for S0D1 
CDK5 一 cycli ո dependent kinase 5 
CMT 一 Charcot-Marie-Tooth 
CNS - central nervous system 
CNTF ― ciliary neurotrophic factor 
COX-2 一 cyclo-oxygenase-2 
DAPI - 4',6-diamidino-2-phenylindole, dihydrochloride 
DMEM - Dulbecco'ร Modified Eagle Medium 
DTT - dithiothreitol 
EAAT2 - excitatory amino acid transporter 2 
ECL 一 enhanced chemiluminescence 
EC SOD - extracellular superoxide dismutase 
EDTA 一 ethylene diamine tetra-acetic acid 
FALS - familial amyotrophic lateral sclerosis 
FCS 一 foetal calf serum 
GEF - guanine nucleotide exchange factor 
HSE ― heat shock element 
HSF 一 heat shock factor 
HSP - heat shock protein 
ICE - interleukin-ß-converting enzyme 
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IF 一 intermediate filament 
IGF-1 一 insulin growth factor-1 
IgG - immunoglobulin G 
IP - immunoprecipitation 
IPTG 一 isopropylthio-ß-D-galactosidase 
kDa 一 kilo Dalton 
LS В - Laemmlľร sample buffer 
MCSs 一 multiple cloning sites 
MEM - Modified Eagle Medium 
MN - motor neurone 
Mn SOD 一 mitochondrial manganese superoxide dismutase 
MT - microtubule 
MTOC 一 microtubule organising centre 
NF - neurofilamnet 
NO - nitric oxide 
P - pellet 
PAGE - Polyacrylamide gel electrophoresis 
PBS - phosphate buffered saline 
PCR - polymerase chain reaction 
PMSF 一 phenlmethylsulphonyl fluoride 
SALS - sporadic amyotrophic lateral sclerosis 
SBMA - spinobulbar muscular atrophy (or Kennedy's disease) 
SCA-1 一 spinocerebellar ataxia type-1 
SDS 一 sodium dodecyl sulphate 
SEC^-Size exclusion chromatography 
sHSP - small heat shock protein 
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SMA - spinal muscular atrophy 
SN 一 supernatant 
snRNP - small nuclear ribonucleoprotein 
S0D1 一 Cu/Zn superoxide dismutase 
TBS 一 tris buffered saline 
TNF-a - tumour necrosis factor-α 
TRITC 一 tetramethylrhodamine isothiocyanateTTBS 
TTBS - TBS containing 0.2% (v/v) Tween 
Ub - ubiquitin 
UPS 一 ubiquitin proteasome system 
wt 一 wild type 




Amyotrophic Lateral Sclerosis: background and clinical aspects 
The motor neurone diseases are a group of heterogeneous disorders, which 
affect motor neurones (MNs). MNs are large nerve cells which are the effectors 
of the nervous system. They relay processed information from the brain to the 
muscle, thereby controlling muscle movement. Upper MNs originate in the brain 
and pass down the spinal cord towards the body. Lower MNs leave the spinal 
cord in ventral roots and innervate their specific effector muscles. Motor 
neurone diseases are characterised by muscle weakness and/or spastic 
paralysis, which results from damage to MNs. The most common adult onset 
motor neurone disease is amyotrophic lateral sclerosis (ALS). Other motor 
neurone diseases include spinobulbar muscular atrophy (SBMA or Kennedy's 
disease), spinal muscular atrophy (SMA) and hereditary spastic paraplegia. 
SBMA and SMA affect lower MNs and hereditary spastic paraplegia affects 
upper MNs. 
ALS was first described by Charcot in 1869. The disease has an 
incidence of 2 in 100,000 and an approximate worldwide prevalence of 7 in 
100,000 individuals. It is estimated that up to 5000 people in the UK have ALS. 
Although ALS can affect any adult individual, the highest occurrence is in the 
50-70 year age range, with men being slightly more affected than women. Loss 
of both upper and lower MNs occurs in ALS, giving rise to muscle atrophy, 
stiffness and fasciculation (muscle twitching). It is less well recognised that 
approximately 30% of small interneurons in the motor cortex and spinal cord 
also degenerate. The progressive decline in muscle function seen in ALS 
results in paralysis, speech defects and eventually death, due to respiratory 
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failure (from denervation of respiratory muscles and the diaphragm). This 
usually occurs within one to five years of clinical onset. In ALS patients, as well 
as MN loss, various abnormalities have been observed in the remaining MNs. 
Proximal axonal swellings, termed spheroids, occur and these have been 
shown to contain neurofilaments (NFs) (Carpenter, 1968). other protein 
accumulations are also observed, and these have been shown to contain 
ubiquitin (Ub) (Leigh et al., 1991). Furthermore, fragmentation of the Golgi 
apparatus is also a prominent feature (Gonatas et al., 1992). The primary 
pathogenic processes underlying ALS are presently unknown, but it is probably 
the case that multiple factors contribute to the disease mechanism. Major 
hypotheses have been put forward to explain disease progression, and these 
include cytoskeletal abnormalities (Xu et al., 1993, Cote et al., 1993), 
excitotoxicity (Rothstein et al., 1992, Shaw et al., 1994) and protein aggregation 
(Deng et al., 1993, Shibata et al., 1996, Durham et al., 1997). These and some 
other contributing factors are discussed in detail in later sections. 
Mutant genes in ALS 
Approximately 10% of all ALS cases are inherited; familial amyotrophic lateral 
sclerosis (FALS). Of these, 20% are caused by mutations in the superoxide 
dismutase 1 (S0D1) gene (Rosen, 1993), and most of these follow an 
autosomal dominant pattern of inheritance. Despite this fact, the disease 
pathogenesis in FALS and sporadic amyotrophic lateral sclerosis (SALS) cases 
is remarkably similar. S0D1, located on chromosome 21q22.1, encodes Cu/Zn 
superoxide dismutase (SODI), a ubiquitously expressed cytosolic metallo-
enzyme which catalyses the conversion of superoxide radicals (a by-product of 
oxidative phosphorylation in the mitochondria) to hydrogen peroxide (H2O2) and 
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water (H2O) (Fridovich, 1986). The S O D I protein is ล homodimer consisting of 
153 amino acids with copper and zinc binding sites. There are two other forms 
of SOD: extracellular SOD (EC SOD) and manganese SOD (Mn SOD), which is 
located in mitochondria. Presently, eighty-nine mutations in S 0 D 1 have been 
linked to ALS. These are widely, albeit unevenly distr ibuted throughout the 
gene, and in most cases are mis-sense mutations occurring in exons 4 and 5 
(Gaudette et al., 2000, Andersen, 2001 , Andersen et al., 2003). An updated list 
of these mutations can be found at http://www.alsod.orq： the online database for 
ALS genetics. 
Other mutations have also been linked to ALS. Mutations in glutamate 
transporters have been reported in SALS cases (Aoki et al., 1998), and a 
mutation in dynactin, a protein involved in axonal transport, leads to lower motor 
neurone disease (Puis et al., 2003). Mutations in NFs are also involved. Some 
SALS patients show mutations in NF subunits (Al-Chalabi et al., 1999), and 
similarly, a mutation in the light NF subunit is the primary cause of Charcot-
Marie-Tooth (CMT) disease type 11. 
ALS2 is a recessive form of juvenile ALS, which is a rare, slowly 
progressing disease which has been mapped to chromosome 2q33 (Mentati et 
al., 1994). Hadano et al., (2001), reported two independent mutations in the 
same gene, ALS2, in two unrelated families with the disease. Other related MN 
disorders have also been identified as being linked to mutations in this gene 
(Yang et al., 2001). ALS2 is expressed in various t issues and cell types, 
including neurons in the brain and spinal cord, and encodes a 184kDa protein; 
alsin, which contains 3 guanine nucleotide exchange factor (GEF) domains. 
One mutation (in Tunisian ALS2) results in the generat ion of a truncated 
protein, and the other, (Kuwaiti ALS2), is a frameshif t mutat ion which results in 
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the generation of seventy new amino acids before a premature stop codon. 
o t o m o et al., (2003), employed biochemical and cell biological analyses to 
determine the functions of alsin and demonstrated that it binds specifically to a 
small GTPase, Rab5， involved in endosomal traff icking. Alsin localises with 
Rab5 and early endosomal antigen-1 (EEA-1) onto early endosomal 
compartments and stimulates endosomal enlargement in vitro. These data 
suggest a role for alsin as a Rab5 GEF and implicate the disruption of 
endosomal dynamics in ALS2. A subsequent report, (Yamanaka et al., 2003), 
demonstrated that ALS2 mutants are highly unstable, as these proteins could 
not be detected in lymphoblasts from patients suffering f rom this form of the 
disease. As a result they proposed that the loss of function of alsin results in 
MN degenerat ion in these MN disorders. 
Two recent reports have implicated mutant small heat shock proteins 
(sHSPs) in neurodegenerat ive diseases. Mutations in HSP 27 have been linked 
to CMT disease and distal hereditary motor neuropathy (Evgrafov et al., 2004), 
and the viability of neuronal cells transfected with mutated HSP 27 was reduced 
when compared to cells expressing wt protein. Similarly, mutations in HSP 22 
have been identified in families with distal hereditary motor neuropathies (Irobi 
et al., 2004) and cultured cells transfected with mutated HSP 22 formed 
intracellular inclusions. 
Continuing research is being carried out to try and identify other 
candidate genes that might be involved in ALS; indeed in 2003, three 
independent reports were published which, in three separate families, l inked 
FALS to a locus on chromosome 16q12.1-16q12.2. Also of interest is the report 
that a mouse mpdifLer gene has been identified that can suppress ALS onset 
(Kunst et al., 2000). The region of chromosome 13 linked to the delayed onset 
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of the disease in these mice contains candidate genes such as SMN (survival 
motor neuron) and NAİP (neuronal apoptosis inhibitor protein) (Kunst et al., 
2000). Both genes have been linked to SMA. The identification of the gene(ร) 
that are able to suppress ALS in this mouse model may help to elucidate the 
disease mechanisms in ALS. 
Mutant SODI-linked FALS 
The mechanism whereby mutant S O D I gives rise to ALS remains unclear. 
What is well establ ished, however, is that it is not loss of function of S 0 D 1 , but 
rather one or more toxic gain of functions that gives rise to the disease. 
Evidence for this toxic gain of function includes: (a) S 0 D 1 null mice do not 
develop motor neuron disease (Reaume et al., 1996). In this study, a mouse 
line was produced with targeted inactivation of the S 0 D 1 gene. These mice, 
shown to be deficient in cytosolic S O D I , develop normally with no evidence of 
motor neuron disease. Whereas mutant S 0 D 1 transgenic mice (Gurney et al., 
1994, Wong et al., 1995) demonstrate limb tremors and neuronal pathology as 
early as 3 months of age, S O D I null mice show no detectable morphological 
changes in the spinal cord by 4 months of age and no motor deficits by 6 
months of age. (b) S 0 D 1 activity in a mutant S 0 D 1 transgenic mouse model 
remains unchanged (Ripps et al., 1995) and mice expressing G37R mutant 
S 0 D 1 in the presence of elevated levels of wild-type (wt) S 0 D 1 develop ALS 
(Wong et al., 1995). (с) changes in wt S 0 D 1 levels in transgenic mutant S 0 D 1 
mice do not affect disease (Bruijn et al., 1998). Here, the effect of wt S 0 D 1 on 
the onset and progression of ALS was determined by either increasing or 
el iminating wt S 0 D 1 in mutant S 0 D 1 transgenic mice. Increasing wt S 0 D 1 
levels in G85R mutant S 0 Đ 1 transgenic mice had no affect on either the t ime of 
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onset or disease progression and did not affect disease pathology; both MN 
degenerat ion and death remained the same, independent of S 0 D 1 level. 
Similarly, either decreasing or eliminating wt S O D I had no effect in G85R 
mutant S 0 D 1 transgenic mice: disease onset and progression remained 
unchanged, as did MN degeneration and death, (d) some mutant forms of 
S O D I retain full activity. A study looking at the specific activities of 6 different 
mutant S O D İ S (Borchelt et al., 1994), showed that although the G85R mutant 
lacked activity, the G37R mutant demonstrated specific activity which was 
greater than or equal to that of wt S 0 D 1 . Four other mutants, namely A4V, 
G41D, G93C and I113T, retained 30-65% of wt specific activity, (θ) disease 
onset and progression do not appear to correlate to S 0 D 1 activity levels 
(Bowling et al., 1995). 
Mutant S0D1 mediated toxicity is non-cell autonomous 
Expression of S O D I is ubiquitous, so why is it that MNs alone are affected in 
mutant S 0 D 1 linked FALS? When mutant S 0 D 1 is selectively expressed in 
astrocytes (Gong et al., 2000), or MNs (Lino et al., 2002), mice do not develop 
any kind of motor neurone disease. Using chimeric mice, (Clement et al., 2003), 
demonstrated that mutant S 0 D 1 toxicity to MNs is non-cell autonomous, i.e. 
damage to both neuronal and non-neuronal cells is required for mutant S 0 D 1 -
mediated toxicity. In these experiments, MNs which expressed either G37R or 
G93A mutant S 0 D 1 at levels which usually cause disease, could escape 
degenerat ion and death if surrounded by normal non-neuronal cells. Another 
interesting f inding was that normal MNs, surrounded by mutant S 0 D 1 
expressing non-neuronal cells, acquired Ub containing deposits. This suggests 
that the presence of mutant S 0 D 1 in these non-neuronal cells may somehow 
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induce protein aggregation in MNs. These data show that the cellular 
environment is important in ALS pathogenesis and that dysfunction and death 
of MNs is partially dependent on support f rom surrounding non-neuronal cells. 
Mutant S0D1 transgenic mice 
Three of the FALS-l inked S 0 D 1 mutations have been characterised in mouse 
models of ALS, namely G37R, G85R and G93A (Gurney et al., 1994, Wong et 
al., 1995, Ripps et al., 1995). Mice expressing these mutant S O D I transgenes 
develop an age-dependent ALS-l ike disorder, exhibiting hind limb weakness, 
degenerat ion of spinal cord MNs, increased astrogliosis, activation of microglia 
and presence of NF- and Ub-containing cytoplasmic inclusions in surviving MNs 
and astrocytes. Such mice have provided a useful tool in the study of mutant 
S0D1- l inked ALS pathogenesis. 
Is aberrant catalytic activity the cause of mutant S0D1 toxicity? 
It is possible that mutant S O D I toxicity may be caused by aberrant enzymatic 
activity. It has been suggested that disruption of amino acids in and around the 
active site may cause conformational changes in mutant S 0 D 1 thus resulting in 
greater access to abnormal substrates. One of these is peroxynitrite (ONOa") 
which is produced by the reaction between S 0 D 1 and nitric oxide (NO) and is a 
powerful oxidant. It reacts with S O D I to produce a nitronium-like intermediate, 
which nitrates tyrosine residues (Beckman, 1993). Thus mutant S 0 D 1 toxicity 
may be mediated by increased nitration of proteins, which is damaging to the 
cell. Increased levels of free nitrotyrosine have been reported in ALS (Beai et 
al., 1997, Bruijn et al., 1997a). Direct biochemical measurement and 
immunohistochemical studies demonstrated increased concentrat ions of free 3-
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nitrotyrosine and its major metabolite, 3-nitro-4-hydroxyphenylacetic acid, in the 
spinal cord of ALS patients. Elevated 3-nitrotyrosine was also detected in the 
MNs of ALS patients (Beai et al., 1997). Another report demonstrated that, 
although increased levels of 3-nitrotyrosine in G37R mutant S 0 D 1 transgenic 
mice are detectable, no such increase in protein bound nitrotyrosine in either 
the spinal cord or MNs of these mice, or in spinal cord extracts f rom ALS 
patients was observed (Bruijn et al., 1997a). Also, levels of nitrated NF are the 
same in both control and ALS cases (Strong et al 1998). These latter reports 
argue against the peroxynitrite/nitration theory and therefore it is unlikely that it 
is a contributing factor in S0D1-med ia ted toxicity. Other evidence opposing this 
theory is that as NO is critical in the formation of peroxynitrite, it would be 
expected that altering NO synthesis would affect disease progression. However, 
a report by Facchinetti et al., (1999) concluded that NO was unlikely to have a 
role in pathogenesis of G93A mutant S 0 D 1 transgenic mice, as the expression 
of G93A mutant S 0 D 1 in a NO null background had no beneficial effect on 
survival, as compared to the expression of G93A alone. 
Another cause of mutant SODI -med ia ted toxicity may be linked to 
hydroxyl radicals. Wiedau-Pazos et al. (1996) have shown that mutant S 0 D 1 is 
able to utilise H2O2as a substrate more efficiently than wt S O D I . This reaction 
produces a highly reactive hydroxyl radical. Toxic hydroxyl radials and the 
resultant oxidative damage have been shown to be increased in the spinal cord 
of mutant SOD1 transgenic mice, coincident with features of motor neuron 
disease (Ferrante et al., 1997, Bogdanov et al., 1998). However, another report, 
(Bruijn et al., 1997a), showed that levels of hydroxyl radicals and lipid 
peroxidation (arising f rom free radical-mediated damage) remain unchanged in 
G37R mutant S 0 D 1 transgenic mice, compared with non-transgenic control 
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l i ttermates. These conflicting data would suggest that hydroxy I radicals are 
unlikely to be a contributing factor in SODI -med ia ted toxicity. 
The report by Bruijn et al., (1998), also disagrees with the aberrant 
catalysis hypothesis. If more efficient use of peroxynitrite by mutant S 0 D 1 has a 
role in disease pathogenesis, then altering the levels of wt S O D I in G85R 
mutant S 0 D 1 transgenic mice would be expected to alter disease progression. 
However, this report demonstrates that this is not the case. In the case of H2O2 
the same reasoning applies: if mutant S 0 D 1 utilises H2O2 more efficiently than 
wt S 0 D 1 , then altering the levels of wt S O D I in the G85R mutant S 0 D 1 
transgenic mice should alter disease progression. However, this is not the case. 
That wt S 0 D 1 does not influence disease in mutant S 0 D 1 transgenic mice 
chal lenges the idea that toxicity arises from increased oxidative stress. 
Both hypotheses of aberrant catalytic activity as a possible cause of 
toxicity ultimately involve copper, as this element acts as a co-factor for S 0 D 1 , 
interacting with substrates in the active site. In 1997, Culotta et al. showed that 
in yeast, copper loading onto S 0 D 1 is dependent on a specific copper 
chaperone - CCS: copper chaperone for S O D I . Subsequent studies have 
shown that wt and various S 0 D 1 mutant proteins bind copper via the action of 
CCS. This supports a hypothesis that aberrant copper mediated chemistry, 
catalysed by less tightly folded mutant S 0 D 1 enzymes, may be responsible for 
MN degenerat ion (Corson et al., 1998). Elimination of CCS in mutant S 0 D 1 
transgenic mice had no effect on either disease onset or progression, showing 
that CCS-dependent copper loading of mutant S 0 D 1 plays no role in disease 
pathogenesis in these mice (Subramaniam et al., 2002). However, CCS is not 
the only means by which S O D I can acquire copper. It has recently been shown 
that S 0 D 1 can acquire copper via a conserved auxil iary pathway that is 
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dependant on the presence of reduced gluathione (GSH) (Carroll et al., 2004). 
Wang et al., (2002), generated transgenic mice that express S 0 D 1 carrying 
disease l inked-mutations which disrupt 2 of the 4 histidine residues which are 
crucial for copper binding; H46R and H48Q. These mice Stil develop motor 
neurone disease, showing that disruption of copper binding does not eliminate 
toxicity. 
The role of zinc in disease pathogenesis 
Like copper, zinc acts as a co-factor for enzymatical ly active S 0 D 1 . Is it 
possible that zinc may also have some role in ALS? It has been shown that, 
compared to wt S O D 1 , FALS-associated S 0 D 1 mutants have dramatically 
different metal binding and redox behaviour, (Lyons et al., 1996). A subsequent 
study demonstrated that the zinc affinity of four FALS-associated S 0 D 1 
mutants is decreased by approximately 30-fold, compared to wt. Such a loss of 
zinc resulted in an increased efficiency of peroxynitr i te-mediated tyrosine 
nitration (Crow et al., 1997). 
This decreased affinity of mutant S 0 D 1 for zinc and the associated 
increase in tyrosine nitration induced MN death via apoptosis (Estevez et al., 
1999). As NO is required for peroxynitrite production (Beckman, 1993), NO 
synthase (NOS) inhibitors, as well as peroxynitrite scavengers, prevent this zinc 
deficient SODI -med ia ted apoptosis. Estevez et al., (1999) also showed that 
copper must be associated with zinc-deficient S O D I in order for the induction of 
apoptosis to occur. Therefore, the authors propose that inactivation of zinc-
deficient S 0 D 1 by means of copper chelating compounds may be of therapeutic 
signif icance in treatment of ALS. 
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Mutations in S O D I account for approximately 2 0 % of inherited FALS 
cases. A possible mechanism for toxicity of mutant S 0 D 1 have been discussed 
above, namely aberrant catalysis. It ¡S also possible that mutant S 0 D 1 mediates 
its toxicity by incorrect protein folding and the subsequent downstream effects 
of this. This will be discussed in a later section: Protein aggregation. But this 
aside, what is happening to cause disease เท the majority of other cases of 
ALS? So far, studies suggest that ALS is a multi-factorial disease with a number 
of contributing factors, some of which are outl ined below. However, how all 
these different factors are linked together and give rise to a remarkably similar 
disease pathogenesis remains unclear and is the subject of ongoing 
investigation. 
Cytoskeletal involvement in ALS: Neurofilaments 
Neurofi laments are the major intermediate f i laments (IFs) in MNs. They are 
formed by co-polymerisation of three different subunits: NF-light (NF-L), 61 kD; 
NF-medium (NF-M), 90kD and NF-heavy (NF-H), 115kD. Both the accumulat ion 
and abnormal assembly of NFs are pathological hallmarks of several 
neurodegenerat ive diseases, including ALS (Carpenter 1968). Two reports in 
1993, (Xu et al., and Cote et al.), showed that over-expression of NF subunits 
can cause death and degeneration of MNs and these observations led to the 
proposal that the pathogenesis of ALS is linked to damage of NFs. Indeed, both 
the content and organisation of NFs influence the disease in mutant S 0 D 1 
transgenic mice: deletion of NF-L increases the l ifespan of G85R mutant S 0 D 1 
transgenic mice (Wil l iamson et al., 1998) and similar results were obtained by 
increasing the expression of NF-H in G37R mutant S 0 D 1 transgenic mice 
(Couii larđ-Despres et al., 1998) and either NF-L or ֊H in G93A mutant S 0 D 1 
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transgenic mice (Kong and Xu, 2000). These genetic manipulations have the 
overall effect of increasing the amount of NFs in the perikarya and decreasing 
NFs in the axons of MNs. However, as to how this increases longevity is as yet 
not known. It has been suggested that elevated levels of NFs in the cell body 
may act as a phosphorylation sink for deregulated cycli ո dependent kinase 5 
(CDK5) activity (Nguyen et al., 2001). CDK5 activity is abnormally increased in 
the spinal cord of G37R mutant S 0 D 1 transgenic mice and this is associated 
with hyperphosphorylat ion of NFs. The authors propose that in these mice the 
NF accumulat ions act as a phosphorylaion sink for the deregulated CDK5 
activity, thereby decreasing the potential hyperphosphorylat ion of other cellular 
substrates. 
Neurof i lament accumulat ions, which are hallmarks of ALS (Carpenter, 
1968), can be phosphorylated, as shown by labelling with phosphorylat ion 
specific antibodies (Sobue et al., 1990). A recent report (Ackerley et al., 2004), 
has shown that a major stress-activated kinase in the nervous system; p38a, is 
also able to phosphorylate NFs. The precise role of NF phosphorylat ion is not 
clear at present, but it has been associated with slowing of axonal transport 
(Jung et al., 2000). Such retardation of axonal transport is an early pathological 
feature in mutant S 0 D 1 transgenic mice (Zhang et al., 1997, Wil l iamson and 
Cleveland, 1999), so it is possible that aberrant activation of p38a may have a 
role in this aspect of the disease. Indeed, p38a is associated with aberrantly 
phosphorylated NFs in human ALS cases (Ackerley et al., 2004). There is other 
evidence support ing such a role for p38a. Tortarolo et al., (2003), demonstrated 
increased p38a activity in the spinal cords of G93A mutant S 0 D 1 transgenic 
mice and minocycline, an anti- inf lammatory drug which delays onset and slows 
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disease progression in G37R mutant S 0 D 1 mice, inhibits p38a (Kriz et al., 
2002). 
It has been shown previously that a mutation in NF-L is a primary cause 
of CMT disease type 11 (Mersiyanova et al., 2000, De Jonghe et al., 2001), a 
related neurodegenerative disease, and Al-Chalabi et al. (1999) have identified 
a set of inframe deletions or insertions in the NF-H tail domain in a small 
proportion of SALS cases. Therefore, it seems that both NF content and 
organisation are important risk factors and contributors in ALS but do not, by 
themselves, have a direct role in the cause of disease. 
Cytoskeletal involvement in ALS: Peripherin 
Peripherin is another neuronal IF, of 57kDa. It is expressed mainly in the 
peripheral nervous system (PNS) but it is also seen at low levels in defined 
populations of neurons in the central nervous system (CNS). It has been 
proposed that peripherin may have a role in neuronal regeneration, as its 
expression is upregulated fol lowing neuronal injury (Troy et al., 1990). In 1992, 
Corbo and Hays reported that peripherin co-localised with NF protein in axonal 
inclusions in MNs of ALS patients, thus suggesting a possible involvement of 
peripherin in ALS. It has since been shown that over-expression of a peripherin 
transgene in mice led to late onset motor neuron disease, characterised by 
formation of ALS-l ike IF inclusions (Beaulieu et al., 1999) and that over-
expression of peripherin in cultured neurons causes apoptotic death in synergy 
with tumour necrosis factor-α (TNF-α) (Robertson et al., 2001). This may 
account for selective neuronal death in ALS. The report by BeauNeu also 
showed that a deficiency in NF-L accelerates the effects of wt peripherin over-
expression. It has been shown that a neurotoxic peripherin isoform, peripherin 
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6 1 , is expressed in G37R mutant S 0 D 1 transgenic mice but not control or 
peripherin transgenic mice, (Robertson et al., 2003). This suggests that 
expression of a neurotoxic splice variant of peripherin is part of the mutant 
S 0 D 1 disease mechanism. Peripherin 61 immunoreactivity was also detected 
in spinal cord MNs from ALS patients. However, notwithstanding all these 
reports, the role of peripherin involvement in ALS was called into question when 
a report (Lariviere et al., 2003) demonstrated that either elimination of all 
peripherin isoforms or over-expression of peripherin had no effect on survival in 
mutant S 0 D 1 transgenic mice. 
Excitotoxicity 
Glutamate mediated excitotoxicity is another potential contributor to ALS. 
Glutamate is a neurotransmitter which activates glutamate receptors, leading to 
depolarisation of neuronal membranes and activation of voltage gated calcium 
( 0 ล ^ ๆ channels (VGCCs). Abnormali t ies in this pathway can lead to 
dysfunctional Ca^"^ homeostasis and cell death. Evidence for glutamate 
mediated excitotoxicity in ALS comes from several reports of elevated levels of 
glutamate in cerebrospinal fluid from ALS patients (Rothstein et al., 1990, 
Rothstein et al., 1991, Shaw et al., 1995). This same finding has now been 
reported in 4 0 % of SALS cases. Synaptic actions of glutamate are terminated 
via glutamate transporters that surround the synaptic cleft. This action protects 
neurons f rom glutamate mediated toxicity. This is supported by evidence from 
the anti-sense knockdown of astroglial glutamate receptors which causes 
excitotoxic neuronal degeneration (Rothstein et al., 1996). Abnormal glutamate 
transport has been reported in ALS (Rothstein et al., 1992, Shaw et al., 1994). 
Different glutamate transporters have been identified and a subsequent study 
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demonstrated that it is loss of the astroglial transporter, excitatory amino acid 
transporter 2 (EAAT2) that is responsible for the abnormal glutamate transport 
seen in ALS (Rothstein et al., 1995). It has been proposed that aberrant RNA 
processing may account for this decrease in EAAT2 levels (Lin et al., 1998) but 
this remains controversial as another report (Meyer et al., 1999) showed that 
aberrant transcripts are present in both ALS cases and control patients. 
Mutations in EAAT2 have been reported (Aoki et al., 1998); N206ร in a SALS 
patient, and a mutation in the 5' end of exon 7 and a silent G to A transition at 
codon 234 at exon 5 in two FALS patients. The N206S mutation occurs at an N-
linked glycosylation site and causes aberrant targeting of the receptor and 
decreased uptake of glutamate by glial cells (Trotti et al., 2001). Glutamate 
mediated excitotoxicity has also been implicated in other neurological diseases 
that resemble ALS (Spencer et al., 1993). In this report, amyotrophic lateral 
sclerosis-Parkinsonism dementia complex (ALS-PDC) has been linked to a 
chronic reliance on native foodstuffs rich in glutamate receptor agonists in 
Guam. 
Other evidence supporting an excitotoxic component in disease 
pathogenesis is the demonstrat ion of reduced Ca^^ binding proteins, for 
example parvalbumin and calbindin D28k, in MNs that are at risk compared to 
those that are spared during the disease. (Alexianu et al., 1994, Ince et al., 
1993). 
Glutamate mediated excitotoxicity has also provided a mechanistic link 
between SALS and FALS; such links are very rare. A4V and I113T mutant, but 
not wt S O D I cause inactivation of EAAT2 (Trotti et al., 1999) and decreased 
levels of EAAT2 are observed in a mutant S 0 D 1 transgenic rat model of ALS 
(Howland et al., 2002). Although S O D I has been implicated in glutamate 
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mediated excitotoxicity, its primary effects are in the MNs: astrogliosis occurs in 
mutant S 0 D 1 transgenic mice after the first clinical symptoms of disease 
appear (Levine et al., 1999) and targeted expression of mutant S 0 D 1 in glial 
cells does not result in disease in mice (Gong et al., 2000). 
From the results described above it can be concluded that glutamate 
mediated excitotoxicity is an important contributor to neuronal death and ALS. 
Furthermore, Riluzole, a drug that acts by decreasing glutamate toxicity, is the 
only FDA (Food and Drug Administration) approved therapy for ALS. 
Mitochondrial defects 
In 1998 Kong and Xu demonstrated that abundant mitochondrial abnormalit ies 
can be detected very early on in disease progression in G93A mutant S 0 D 1 
transgenic mice. The onset of muscle weakness correlates with a massive 
vacuolat ion of mitochondria, suggesting a possible contribution of mutant S 0 D 1 
to disease pathology via mitochondrial degenerat ion. This vacuolation is 
associated with translocation of mutant S 0 D 1 into the inter-membrane space of 
the mitochondria (Jaarsma et al., 2001). Another study has also reported the 
presence of mutant S O D I in CNS mitochondria in G93A mutant S 0 D 1 
transgenic mice (Higgins et al., 2002), o the r evidence support ing a role for 
mitochondrial involvement in ALS includes functional inhibition of mitochondria 
in in vitro cultured MNs inducing cell death (Kaal et al., 2000). Furthermore, a 
partial deficiency of the mitochondrial form of SOD, Mn SOD, exacerbates the 
clinical phenotype and disease progression in G93A mutant S 0 D 1 transgenic 
mice (Andreassen et al., 2000). Also, a report by Borthwick et al., (1999), 
showed a selective decrease in cytochrome с oxidase; a mitochondrial enzyme, 
in spinal cord MNs from ALS patients. Cytochrome с oxidase is encoded by 
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mitochondrial DNA; it may, therefore, be the case that damage to mitochondrial 
DNA is implicated in ALS. 
Two drugs, creatine and minocycline, which target mitochondria have 
been shown to be beneficial in mouse models of ALS. Creatine buffers 
intracellular energy stores and inhibits opening of the mitochondrial transition 
pore. Administration of this to G93A mutant S 0 D 1 transgenic mice improves 
motor performance and protects them from loss of MNs (Klivenyi et al., 1999). 
Similarly, minocycline improves motor performance and also extends survival in 
G93A mutant S 0 D 1 transgenic mice (Zhu et al., 2002). Minocycline has 
neuroprotective properties in other neurodegenerat ive condit ions (e.g. 
Huntingdon's and Parkinson's diseases) and consequently was tested in this 
ALS disease model. This report demonstrated that minocycline exerted its 
effects via inhibition of permeabil i ty transit ion-mediated cyctochrome с release 
in mitochondria. The above reports also present data which implicate 
mitochondrial dysfunction in ALS. However, there is some conflicting evidence 
in that morphologically abnormal mitochondria were not observed in G85R 
mutant S 0 D 1 transgenic mice (Bruijn et al., 1997b) 
Activation of apoptosis 
Bcl2 is an anti-apoptotic protein that has been shown to reduce MN loss in 
mice; it protects against axotomy-induced MN loss after transection of the facial 
nerve (Dubois-Dauphin et al., 1994). This led to a report by (Kostie et al., 1997), 
which demonstrated that over-expression of Bcl2 in G93A mutant S 0 D 1 
transgenic mice delays disease onset by decreasing loss of myel inated nerve 
fibres and death of spinal cord MNs, thereby prolonging survival. This is one of 
many publications linking ALS and increased levels of apoptosis. 
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Using an in vitro neuroblastoma cell model together with mutant S O D I 
transgenic mice (G37R and G85R), (Pasinelli et al., 1998), demonstrated that 
neural cells and tissue expressing mutant S 0 D 1 show cleavage of caspase-
1/interleukin-ß-converting enzyme (ICE). Complete cell death, however, 
requires additional stimuli such as oxidative stress. Caspase-1 and -3 are 
sequentially activated in the spinal cord of G93A mutant S 0 D 1 transgenic mice 
with caspase-3 localised in those neurones which exhibit apoptotic features, 
and over-expression of Bcl2 delays this caspase activation (Vukosavic et al., 
2000). Furthermore, ทาitochondrial-dependent apoptosis is activated in ALS: 
Bax and cytochrome с translocation occurs in the spinal cord of G93A mutant 
S O D I transgenic mice. Cytochrome с is translocated out of the mitochondria, 
activating caspase-9, which then leads to activation of downstream effector 
caspases; caspase-3 and -7. In this study (Guegan et al., 2001), the authors 
also demonstrated that X-chromosome linked inhibitor of apoptosis protein 
(XIAP) is cleaved and consequently inactivated. 
This link with apoptosis is also implicated in two studies which both 
demonstrate that inhibitors of apoptotic proteins have beneficial effects in 
mouse models of the disease. Expression of a dominant negative form of ICE in 
G93R mutant S 0 D 1 transgenic mice slows disease progression (Friedlander et 
al., 1997), and pharmacological inhibition of caspase activity using N-
benzyloxycarbonyl-Val-Asp-f luoromethylketone (zVAD-fmk), a broad range 
caspase inhibitor, delays disease onset and prolongs l ifespan in G93A mutant 
S 0 D 1 transgenic mice (น et al., 2000). 
Activation of apoptosis has been demonstrated in ALS patients as well 
as in mutant S 0 D 1 transgenic mice. One of the hallmarks of apoptosis, DNA 
fragmentat ion, has been observed in CNS regions of ALS cases, together with 
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increases in both caspase-3 and the pro-apoptotic Bax and Bak in the 
mitochondria (Martin, 1999). Prostate apoptosis response-4 (Par-4), a protein 
induced in prostate cancer cells and neuronal apoptosis, is also increased in the 
spinal cord MNs of ALS patients (Pedersen et al. , 2000). 
Despite this huge body of evidence, which together demonstrates that 
the apoptotic process is activated in ALS, a report by (Migheli et al., 1999) 
demonstrated a lack of apoptosis in G93A mutant S O D I transgenic mice. No 
DNA fragmentat ion has been observed in the MNs of these mice and 
immunohistochemical studies revealed no neuronal staining with antibodies 
specific for apoptosis-related proteins, e.g. activated caspase-3. 
A x o n a l t r a n s p o r t and m o t o r p ro te i ns 
Axonal transport has been implicated in ALS and related neurodegenerat ive 
diseases. The slowing of axonal transport is an early pathological feature in 
both G37R and G85R mutant S 0 D 1 transgenic mice (Wil l iamson and 
Cleveland, 1999). In CMT disease type 11 mutant NFs inhibit axonal transport of 
both NFs and mitochondria in cultured cortical and dorsal root ganglion 
neurones (Brownlees et al. , 2002) . 
More recently, dynein, a specific component of axonal transport, has 
been linked to ALS (LaMonte et al . , 2002, Hafezparast et al. , 2003, Puls et al., 
2003). Dynein, a motor protein responsible for retrograde transport along 
microtubules (MTร), has multiple cellular functions, including endoplasmic 
reticulum (ER) to Golgi traff icking and mitotic spindle assembly, but as yet is the 
only known motor protein which has been shown to play a role in retrograde 
transport in neurones. Dynein is activated by a mult iprotein complex called 
dynactin and in mice over-expression of the dynamit in subunit of dynactin 
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renders dynactin non-functional, thereby reducing retrograde axonal transport. 
This leads to degenerat ion of MNs and development of an ALS-l ike phenotype 
in these mice (LaMonte et al. , 2002). Mutations in dynein and related proteins 
have now been reported to cause MN disorders. Hafezparast et al. (2003) 
reported that mutations in the heavy chain of dynein perturb its neuron-specif ic 
functions and lead to progressive MN degenerat ion in mice. Puis et al. (2003) 
have identified a mutation in the gene encoding a subunit of dynactin in a family 
with slow progressing autosomal-dominant lower motor neuron disease. It is 
also possible that NF accumulat ions, a common feature of ALS pathogenesis 
(Carpenter, 1968), may be linked to disruptions in the axonal retrograde 
transport machinery. 
G r o w t h fac to r i n v o l v e m e n t i n A L S : vascu la r endo the l i a l g r o w t h f ac to r 
Given that vascular endothelial growth factor (VEGF) controls the growth and 
permeabil i ty of blood vessels, it is somewhat surprising that a link between 
VEGF and ALS has been observed. VEGF is rapidly up-regulated in response 
to changes in oxygen levels. Through their binding to the hypoxia response 
element in the VEGF promoter, hypoxia-inducible factors are essential in this 
response. Impaired hypoxic regulation of VEGF has been shown to be a risk 
factor for ischemic heart disease (Schultz et al . , 1999). Following on from this, 
Oosthuyse et al. , (2001)， created mice with targeted deletion of the hypoxia 
response element; decreasing baseline and hypoxic induction of VEGF, in order 
to study the relevance of hypoxic regulation of this growth factor in ALS. These 
mice developed severe adult onset muscle weakness due to degenerat ion of 
- lower MNs; symptoms which resemble ALS. 
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To determine whether VEGF has a role in MN degenerat ion, a large 
European study was carried out (Lambrechts et al. , 2003) . Although they did not 
find any sequence variations in the hypoxia response element of the V E G F 
gene, they identified three single nucleotide polymorphisms in the promoter 
region, which conferred a greater susceptibil ity to ALS. These 'at-risk' 
haplotypes were associated with both reduced V E G F expression and levels of 
circulating VEGF. Lambrechts et al. , (2003), also demonstrated that reduced 
levels of V E G F in G93A mutant S 0 D 1 transgenic mice exacerbate disease 
progression and furthermore, that V E G F protects mice against ischemic MN 
death. 
These results strongly implicate V E G F as an 'at-risk' factor in ALS. 
However, it still remains to be determined whether chronic vascular insufficiency 
is a general contributor to ALS, whether VEGF acts as a neurotrophic factor for 
MNs and whether other hypoxia-inducible neurotrophic factors are involved in 
MN survival. It is also possible that V E G F could be used therapeutically to slow 
the onset and progression of MN degenerat ion in ALS. Indeed, ล recent study 
has shown that retrograde viral delivery of V E G F in G93A mutant S 0 D 1 
transgenic mice delays both disease onset and progression (Azzouz et al. , 
2004). This effect was seen even when V E G F treatment was initiated at the 
t ime of disease onset. These results are extremely promising as disease onset 
occurs prior to the appearance of clinical symptoms and this approach has 
great potential in the treatment of human ALS. 
G r o w t h fac to r i n v o l v e m e n t in A L S : n e u r o t r o p h i c f a c t o r s 
Ciliary neurotrophic factor (CNTF) is an important survival factor for MNs. 
Disruption of the CNTF gene causes MN degenerat ion (Masu et al., 1993) and 
34 
reduced levels of CNTF have been reported in post-mortem ALS patient t issue 
(Anand et al. , 1995). Furthermore, it was reported that a 25 year-old patient, 
who died from FALS carried a null mutation in the CNTF gene as well as a 
V148G mutat ion in the S 0 D 1 gene (Giess et al. , 2002) . When G93A mutant 
S O D I transgenic mice were crossed with CNTF deficient mice the resultant 
progeny, carrying mutations in both the S 0 D 1 and CNTF genes, exhibited 
earlier disease onset and increased MN loss, compared to mice carrying only 
the mutant S O D I gene (Giess et al. , 2002). Based on these findings, it has 
been hypothesised that CNTF is a modifier gene in mutant S 0 D 1 linked FALS. 
However, Takahashi et al., (1994), reported that null mutations in CNTF 
are observed in healthy individuals as well as those with neurological disorders. 
A similar result was presented by A l - ^ ^ et al. , (2003). Two g roups of 
patients with SALS and a group with mutant SODI - l i nked FALS were studied 
and no difference in either disease onset or progression was noted for three 
CNTF phenotypes. Collectively these data suggest that CNTF does not 
influence ALS. 
In addit ion to CNTF, there are other trophic factors which support MNs 
and may be involved in ALS pathogenesis. One of these is insulin growth factor-
1 (IGF-1); retrograde viral delivery of IGF-1 has been shown to be beneficial in 
a mouse model of ALS (Kaspar et al. , 2003). Glial cell l ine-derived neurotrophic 
factor (GDNF) was also tested using this method, but was less effective than 
IGF-1 . The latter growth factor delays MN death, decl ine of motor function and 
prolongs survival, whether delivered prior to or at the t ime of disease onset. 
This study not only provides evidence of the beneficial effect of IGF-1, but also 
that specific targeting of MNs via this method could be util ised further in the 
treatment of the disease. 
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Mic rog l i a a n d i n f l a m m a t i o n 
In ALS patients, microglia activation and proliferation occurs in regions of MN 
loss (Kawamata et al. , 1992). Microglia mediate neuroinf lammation and are 
activated in response to CNS injury. This affects neurons and macrogl ia 
(astrocytes and ol igodendrocytes) via the release of cytokines and pro­
inf lammatory factors. Compared to non-diseased controls, increased levels of 
pro-inf lammatory prostaglandin PGE2 have been reported in ALS cerebrospinal 
f luid, (Aimer et al. , 2002). Cyclo-oxygenase-2 (COX-2); a pro-inf lammatory 
enzyme, and the number of activated microglia are also up-regulated in the 
spinal cord of ALS patients, compared to control samples (Yasoj ima et al., 
2001). 
Similar f indings have been reported in mutant S 0 D 1 transgenic mice. In 
2001 ， Alexianu et al . demonstrated up-regulation of intercellular cell adhesion 
molecule-1 ( ICAM-1), neuronal immunoglobul in G (IgG) deposits and microglial 
and astrocytic activation occur sequential ly during disease progression of G93A 
mutant S 0 D 1 transgenic mice. This suggests that up-regulation of pro­
inf lammatory factors occurs during the pre-symptomatic stages of the disease 
and is fol lowed by expansion of immune activation; mechanisms which may 
contribute to disease progression. Cytokines are secreted by activated microglia 
and astrocytes and may have a role in MN dysfunct ion. Some cytokines, 
including T N F-α, are also up-regulated in G93A mutant S 0 D 1 transgenic mice, 
while others, including interleukins-3 and - 6 (IL-3 and - 6 ) , are not (Elliott, 
2001). Furthermore, TN F-α, in concert with peripherin over-expression is 
required in order to cause death of cultured MNs (Robertson et al . , 2001). 
Increased COX-2 immunoreactivity is seen in G93A mutant S O D I transgenic 
mice (Aimer et al., 2001), in both early symptomat ic and end stage of the 
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disease, and a DNA ทาicroarray study (Olsen et al. , 2001), fol lowing gene 
expression over disease course in G93A mutant S 0 D 1 transgenic mice, has 
shown that microglia and astrocytic activation are coincident with disease onset. 
So although the precise mechanisms and pathways involved remain to 
be determined, there is strong evidence suggesting an inflammatory role in ALS 
pathogenesis. This is further strengthened by the use of COX-2 as a therapeutic 
target. Inhibition of COX-2 has been shown to delay onset of motor dysfunct ion 
in G93A mutant S 0 D 1 transgenic mice (Pompi et al. , 2003). Also, minocycl ine, 
which inhibits microglial activation and reduces inf lammation, delays the onset 
and slows progression of disease in G37R mutant S 0 D 1 transgenic mice (Kriz 
et al. , 2002). 
Pro te in a g g r e g a t i o n 
Proteinaceous aggregates, or inclusions, are a common neuropathological 
feature of many neurodegenerat ive diseases, including ALS, Parkinson's, 
polyglutamine diseases, such as Huntington's, SBMA, and Alzheimer's. A report 
by Johnston et al., (1998), characterised aggregate/inclusion format ion. 
Aggregat ion of protein occurs when the capacity of the proteasomal 
degradation machinery is saturated; either by increased expression of 
substrates or decreased proteasomal activity. They suggest that, once formed, 
these aggregates (or inclusions) are del ivered, via retrograde transport on 
microtubules (MTร), to a Ub-containing structure at the MT organising centre 
(MTOC). Here, they are ensheathed in IF protein, this structure being termed an 
aggresome. Johnston et al. , (1998), propose that aggresome formation is a 
general cellular response to the accumulat ion of un-degraded and aggregated 
protein. However, it is not known whether these aggregates/inclusions 
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themselves are either toxic, thus contributing to neurodegenerat ion in these 
diseases, or whether they comprise a cellular defence mechanism; acting as a 
'sink' where potentially toxic molecules are sequestered. This is discussed by 
(Tran and Miller, 1999), and appears to be dependent on the disease in 
quest ion. Lewy bodies in Parkinson's disease (intracytoplasmic inclusions with 
a dense eosinophil ic core and pale surrounding halo) are thought to have a 
causative role in the disease, whereas the nuclear inclusions observed in the 
polyglutamine diseases are thought to have a protective role (Arrásate et al. , 
2004). 
In ALS, inclusions are generally considered to contribute to 
neurodegenerat ion. Another possible mechanism for mutant S0D1-med ia ted 
toxicity is that mutant S 0 D 1 is mis-folded and consequent ly more prone to 
aggregat ion, resulting in the formation of toxic inclusions. Mutations in S 0 D 1 
occur throughout all 5 exons, suggest ive of altered protein conformat ion; X-ray 
crystal lography has shown that conformation of the active site is indeed altered 
in mutant S O D I (Deng et al., 1993). Over-expression of mutant but not wt 
S O D I in primary neuronal cultures leads to inclusion formation and such 
inclusions are toxic, resulting in cell death (Durham et al. , 1997). 
Intracytoplasmic, SOD 1-containing inclusions are observed in MNs and 
astrocytes of G85R mutant S O D I transgenic mice (Bruijn et al. , 1998)， and in 
spinal cord samples f rom FALS patients (Shibata et al. , 1996). If these 
inclusions are themselves toxic, this could be exerted in a variety of ways: 
firstly, they could co-aggregate with other proteins, deplet ing the cell of 
essential components; secondly, they could burden the ubiquitin proteasome 
system (UPS), (as shown by Bence et al. , 2001) , preventing degradat ion of 
other proteins (of particular importance in this case are regülätory proteins, for 
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example cyclinร and transcription factors), and thirdly, they could also disrupt 
axonal dependent MT transport. 
Chaperone proteins facilitate in the refolding of proteins, and this may be 
a key factor in the ability of cells to defend themselves against aggregat ion of 
mutant S 0 D 1 . In a report by Bruening et al. , (1999), chaperone proteins were 
shown to be up-regulated in cells and t issues containing mutant, but not wt, 
S 0 D 1 . However, this up-regulation was not observed in the spinal cord of 
mutant S 0 D 1 transgenic mice. This led to the hypothesis that mutant, mis-
folded S 0 D 1 , present within a cell is likely to divert chaperone proteins towards 
trying to refold it. This could have a detr imental affect on the cell, as the 
chaperones are diverted away f rom the refolding of other proteins, leading to 
more aggregat ion, thus rendering the cell more susceptible to other stresses, 
both physiological and environmental . Such stress could contribute to 
dysfunction and death. Most cells are able to up-regulate chaperones, so the 
mutant S O D I would not create such a problem. However, it may be the case 
that MNs are deficient in the ability to up-regulate chaperones in response to 
stress. They are also already exposed to the physiological stress of a high 
excitatory input, due to their role in relaying electrical impulses and effecting 
muscle movement , and this adds to the overall burden. This hypothesis also 
goes some way to explaining the selective vulnerabil ity of MNs in ALS. In order 
to test this hypothesis, Bruening et al . , (1999), co-injected heat shock protein 
(HSP) 70 and mutant S 0 D 1 into cultured primary MNs. This resulted in a 
decrease in the number of cells containing mutant S 0 D 1 inclusions and 
prolonged cell survival. 
Mutant S O D I from NIH3T3 cell extracts and G93A mutant S 0 D 1 
transgenic mice spinal cord extract is detergent insoluble, and chaperorie 
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proteins, namely HSPs 70, 40 and aB-ctystal l in, co- immunoprecipi tate with 
mutant S 0 D 1 from NIH3T3 cells (Shinder et al. , 2001). Again, it has been 
suggested that mutant S 0 D 1 inclusions may result f rom an inadequate stress 
response. Indeed, MNs have a high threshold for induction of the stress 
response, (an overview of this fol lows in a later sect ion, The heat shock 
response). Takeuchi et al. , (2002), have shown that mutant, but not wt， S 0 D 1 
induces inclusion formation, fewer neurites and cell death in a neuroblastoma 
(Neuro2a) cell line. This supports the hypothesis that inclusion formation 
contributes to cellular dysfunction in neurodegenerat ive disease. Over-
expression of HSPs 70 and 40 suppresses aggregation of mutant S O D I , 
promotes neu rite outgrowth and suppresses cell death in this same cell line. 
More recently, Kieran et al. , (2004), reported that up-regulation of HSPs 
in a mouse model of ALS increases the life expectancy of these animals. Here, 
ar imoclomol, a drug which acts as a co-inducer of HSPs, was used to treat 
G93A mutant S 0 D 1 transgenic mice. This treatment resulted in a 2 2 % increase 
in l i fespan, due to an improvement in muscle function and increased MN 
survival. HSPs have also been shown to be protective in other 
neurodegenerat ive diseases. Using a Drosophila melanogaster model of 
polygi utam і ne disease, (Warrick et al. , 1999), showed that directed expression 
of HSP 70 suppressed polyglutamine mediated neurodegenerat ion. Over-
expression of HSPs 70 and 40 reduced aggregate formation and suppressed 
apoptosis in a neuronal cell model of SBMA (Kobayashi et al. , 2000). 
Spinocerebel lar ataxia type 1 (SCA1) is another example of a polyglutamine 
disease. High levels of HSP 70 in SCA1 transgenic mice were shown to 
suppress neuropathology and improve motor function (Cummings et al. , 2001) . 
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The data discussed above show that chaperone proteins play an 
important role in protein aggregat ion in neurodegenerat ive diseases. Up-
regulation of chaperone proteins suppresses aggregate formation in both cell 
and animal disease models. Also, it has recently been shown that mutations in 
some chaperone proteins, namely HSP 27 (Evgrafov et al., 2004) and HSP 22 
(Irobi et al. , 2004), are l inked to neurodegenerat ive diseases, namely C M T 
disease and distal hereditary motor neuropathy. 
C h a p e r o n e p ro te i ns 
All cells and organelles possess chaperone proteins whose function is to 
support the correct folding of proteins during translation, translocation and 
periods of stress (Buchner, 1996， HartI and Hayer-HartI, 2002). In order to 
perform this role, chaperones differentiate between native and non-native (i.e. 
mis-folded) forms of the target protein. They act by binding un- and mis-folded 
polypeptides, decreasing the probability of irreversible interactions of exposed 
hydrophobic regions and consequent ly al lowing the folding and maintenance of 
protein structure under non-permissive condit ions. Such binding is regulated by 
adenosine tr iphosphate (ATP)- induced conformational changes in the 
substrate-binding domain. Chaperones themselves do not convey specific 
information for the folding of the target protein, but instead support correct 
structure by the prevention of aberrant interactions with un- or mis-folded 
proteins within the cell which, in the absence of this surveil lance mechanism, 
may lead to aggregation and inclusion formation (Buchner, 1996, HartI and 
Hayer-HartI , 2002). As well as this role in maintaining the correct folding of 
protein during translat ion, translocation and stress, chaperones have other 
cellular functions, including: (a) translocation of proteins across membranes (b) 
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macromolecular assembly and disassembly (c) transfer of un- and mis-folded 
protein to the proteasome for degradat ion (d) acting as important components 
of signal transduction pathways involved in the stress response. These proteins 
also influence the cell's cytoskeleton, facilitating the formation of cytoskeletal 
elements and performing different, but co-operative roles in regulation of 
cytoskeletal function (Perng et al., 1999a). 
In recent years, most classes of HSPs have been identified as molecular 
chaperones (Buchner, 1996). HSPs are divided into the fol lowing famil ies, 
according to their function, structure and size: small HSPs (sHSPs); HSP60; 
HSP70; HSP90 and HSP100. sHSPs are an abundant and ubiquitous family of 
proteins involved in the stress response. They have molecular weights of 
between 12 and 40kDa and mammal ian sHSPs form ol igomeric structures of 
approximately 32 subunits, corresponding to a molecular weight SOOkDa (Arrigo 
et al., 1988). All sHSPs are characterised by a conserved core a-crystall in 
domain of between 80 and 100 amino acids, in the C-terminal region of the 
protein (deJong et al., 1988). The expression of these proteins is increased 
under heat shock condit ions, and like other chaperones, sHSPs recognise and 
bind denatured protein, thus preventing the formation of aggregates 
independently of ATP (Jakob et al . , 1993). A report by Lee et al. , (1997), 
proposed that other molecular chaperones recognize sHSP-substrate 
complexes and then actively participate in the refolding of the substrate: energy-
independent sHSPs trap non-native proteins during stress condit ions, thus 
protecting them from aggregat ion. Under permissive condit ions, these energy-
dependent chaperones can then complete the refolding of this reservoir of 
folding-competent protein. Thus, sHSPs prevent rapid protein aggregation by 
the initiation of binding events while other chaperones primarily refold non-
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native protein. sHSPs also undergo specific interactions with the cytoskeleton, 
preserving cell shape and integrity (Perng et al . , 1999a) 
Mutations in sHSPs affect their function and these have been linked to 
various diseases (Clark and Muchowski , 2000). The R120G mutation in the 
sHSP aB-crystal l in causes structural alteration, which leads, indirectly to limited 
functioning (Bova et al., 1999, Perng et al . , 1999b, Chavez Zobel et al. , 2003), 
and this has in turn been linked to the cardiovascular disorder, desmin-related 
myopathy (DRM) (Perng et al. , 1999b). Recently, two reports have l inked 
mutations in sHSPs to neurodegenerat ive diseases (I robi et al. , 2004, E vg raf ov 
et al., 2004). Both mutation of K141 in HSP 22 (Irobi et al. , 2004), and ร 1 3 5 in 
HSP 27 (Evgrafov et al . , 2004) lead to structural instability, as these residues 
are located in the core a-crystall in domain. 
The heat s h o c k r e s p o n s e 
An evolutionarily conserved and cytoprotective mechanism 一 the heat shock 
response 一 is mediated in response to stress by increasing levels of 
transcription of genes encoding HSPs. (For a review, see Morimoto et al., 
1997). As a type of chaperone protein, both stress induced and constitutively 
expressed HSPs facilitate nascent protein folding, and re-folding or degradation 
of un- or mis-folded protein. In eukaryotic systems, the action of HSPs is 
mediated by binding of heat shock transcription factors (HSFs) to heat shock 
elements (HSEs), on the promoters of HSPs. Up-regulat ion of HSPs, due to 
environmental and physiological stresses, occurs primarily via the action of heat 
shock factor 1 (HSF1) (Morimoto et al. , 1998). In neural cells, HSPs protect 
against hyperthermia, oxidative stress, ischemia and excitotoxicity (Rordorf et 
al., 1991 , U ney et ăl . , 1993, Y e n a r ľ e f a l . , 1998). 
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As previously discussed, one proposed mechanism for disease 
pathogenesis in ALS is structural changes arising in S 0 D 1 resulting f rom 
mutations, which lead to altered solubility and aggregat ion. Gene transfer of 
HSP 70 in a cell culture model of ALS protects against mutant S 0 D 1 
aggregation (Bruening et al. , 1999). This raised the quest ion as to whether MNs 
are able to initiate a sufficient heat shock response in response to stresses such 
as protein aggregat ion. A study carried out by the same research group, 
(BatuIan et al. , 2003), investigated the endogenous heat shock response in 
MNs and showed that these cells do in fact have a high threshold for response. 
Glia, but not MNs, f rom spinal cord cultures, up-regulate HSP 70 in response to 
heat shock. MNs also failed to up-regulate HSP 70 in response to other 
stresses, including glutamate excitotoxicity and mutant S 0 D 1 . Similar f indings 
were observed in mutant S 0 D 1 transgenic mice and ALS patients. Like HSP 
70， aB-crystal l in and HSP 27, although present in the cytoplasm of MNs, are 
not up-regulated after subjection to stress treatments in vitro, in either mutant 
S O D I transgenic mice or in spinal cord extracts f rom ALS patients. 
Exposure of MNs to heat shock would be expected to activate heat 
shock gene expression via HSF1 (Morimoto, 1998). Inactive HSF1 is either a 
cytoplasmic monomer (Morimoto and Santoro, 1998), or present in nuclear 
granules (Jolly et al . , 2002). In stressed cells, containing insufficient levels of 
HSPs, HSF1 tr imerises and binds HSEs. Multiple phosphorylat ion then causes 
conformational changes, finally resulting เท the recruitment of transcription 
machinery and transcription of heat shock genes (Morimoto and Santoro, 1998). 
Therefore, deficiency of HSP induction in MNs could occur at any of these 
levels. MNs have been shown to express both of the major HSFs: HSF 1 and 2 
(BatuIan et al. , 2003). It may be that the levels of these are insufficient to mount 
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a heat shock response. However, even after micro-injection of a plasmid 
encoding H S F 1 , no increase in HSP 70 expression was detected after heat 
shock. This implies that this impaired ability of MNs may be due to an inability to 
activate HSF1 (Batulan et al., 2003). 
Recently it has been shown that treatment of G93A mutant S O D I 
transgenic mice with a co-inducer of HSPs delays disease progression (Kieran 
et al,, 2004). Ar imoclomol is a hydroxylamine derivative of bimoclomol, which 
acts as a co-inducer of HSP expression (Vigh et al. , 1997). Treatment of these 
G93A mutant S 0 D 1 transgenic mice with this drug resulted in improved muscle 
function and elevated MN survival, giving rise to a 2 2 % increase in l i fespan. 
This family of molecules, of which ar imoclomol and bimoclomol are members, 
has been shown to mediate their affects by prolonging activation of HSF1 
(Hargitai et al. , 2003). So, although MNs have an impaired ability to activate 
HSF1 (Batulan et al., 2003) , therapeutic intervention with a drug that activates 
the heat shock response and subsequent up-regulation of HSPs, via prolonging 
activation of H S F 1 , may allow this deficiency of MNs to be overcome. 
The u b i q u i t i n p r o t e a s o m e s y s t e m 
The UPS is a highly complex and tightly regulated protein degradation system. 
It consists of a 2 6 ร proteasome complex: a large, multi-catalytic protease made 
up of 2 sub-complexes: a 20S core catalytic particle and a 19ร regulatory 
particle. The proteasome not only serves as a mechanism for the degradat ion of 
mis-folded, unassembled or damaged proteins, but it is also able to carry out 
limited proteolysis and post-translational processing (e.g. the proteasome 
processes major histocompatibilty (MHC) class I ant igens and generates active 
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subunits of the transcriptional regulator N F - K B f rom larger, inactive precursors 
(Ciechanover and Brundin, 2003). 
Polyubiquitin acts as a degradation signal in the UPS. The process of 
polyubiquit ination occurs as fol lows, via a system of different enzymes: firstly, 
Ub activating enzyme; E l , activates Ub. Secondly, Ub conjugat ing enzyme; E2, 
transfers the activated Ub to the substrate protein, which itself may be bound by 
Ub-protein l igase; E3. E3ร are the specific substrate recognit ion factors of the 
UPS. Next, a poly-Ub chain is formed, via the processive transfer of Ub to the 
lysine 48 residue of the previous Ub moiety. This polyubiquit inated substrate 
protein is then recognised by the 19ร regulatory particle which results in the 
protein being unfolded prior to degradat ion by the proteasome. This process 
requires ATP and releases free, reusable Ub (Ciechanover and Brundin, 2003). 
The UPS a n d A L S 
The presence of Ub-containing inclusions is frequently observed in many 
neurodegenerat ive diseases. It may be that these inclusions arise as a result of 
failed attempts by the UPS to degrade damaged and abnormal proteins. 
However, it is also possible that they are formed as a protective mechanism, 
removing the soluble fraction of aggregated protein which may be toxic. It is 
probable that the reasons for the presence of these Ub-containing inclusions 
are disease specific. A report by Bence et al., (2001)， demonstrated that 
aggregated proteins can inhibit the UPS. This compl icates matters, as 
aggregated proteins are simultaneously inhibitors of the UPS and the products 
resulting from its inhibition. An increase in protein aggregat ion would inhibit 
UPS activity which in turn leads to further increases in protein aggregat ion, and 
so 一on. This positive feedlDack mechanism ทiäy have a role in the loss of 
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neuronal function which characterises the progression of many of these 
neurodegenerat ive diseases. 
As already discussed, in FALS, 2 0 % of patients have mutations in S O D I . 
Mutant S 0 D 1 , again, as already discussed, is more prone to mis-folding, 
leading to formation of inclusions. Mutant S O D I inclusions in mouse models 
and human FALS patients have been shown to contain Ub (Bruijn et al. , 1998). 
This implicates a role for the UPS in ALS disease pathogenesis. Mutant S 0 D 1 
is less soluble than wt S 0 D 1 and forms high molecular weight complexes in 
non-neuronal cells. The amount of these non-native ol igomers is further 
increased by inhibition of the UPS. Non-native ol igomers are also observed in 
mutant S 0 D 1 transgenic mice (Johnston et al. , 2000). 
Over-expression of an E3 ligase, dorf in, has been shown to prevent cell 
death induced by mutant protein, presumably by promoting its degradation via 
the UPS (Niwa et al . , 2002). Furthermore, dorf in expression has been shown to 
be elevated in the spinal cord of ALS patients (Ishigaki et al. , 2002) and is 
present in inclusions in cases of both FALS and SALS (Niwa et al., 2002). 
The report by Bence et al. , (2001), demonstrated UPS inhibition by 
aggregated protein and there is evidence for this also occurring in ALS. 
Urushitani et al., (2002), have shown that the presence of mutant mis-folded 
S O D I reduces the catalytic activity of the UPS in a neuroblastoma cell line. 
Furthermore, this is not due to incorporation of proteasome components into 
inclusions, as occurs in some other neurodegenerat ive diseases (Cummings et 
al . , 1998). Urushitani et al. , (2002), also proposed a model of disease 
pathogenesis in ALS: mutant, mis-folded and polyubiquit inated S O D I overloads 
the UPS, leading to its further accumulat ion. Such accumulat ion will have an 
affect on the normal functioning of S 0 D 1 i.e. it will càuse impairment of the 
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defence mechanisms that protect against oxidative stress. As a consequence of 
this, the increased stress may cause further mis-folding of proteins, including 
mutant S 0 D 1 , thereby exacerbating the substrate overload on the UPS even 
further. All this results in a self-perpetuating cycle occurring within the cell. 
Is it possible that MNs are particularly vulnerable to UPS inhibition? It is 
MNs that are selectively affected in ALS, and, compared to non-neuronal cells, 
cultured MNs show a significant decrease in viability in the presence of the 
proteasome inhibitor lactacystin (บrushitani et al., 2002). However, despite the 
data discussed above, the role of protein aggregation and the UPS in ALS 
remain unclear. 
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Aims of the study 
This chapter has discussed the wide range of contributing factors in the disease 
pathogenesis of ALS, both in mouse models of the disease and ALS patients. 
One of the major hypotheses for the cause of mutant S0D1-linked FALS, is 
protein aggregation. Mutant S0D1 is mis-folded and consequently prone to 
aggregation, leading to the formation of S0D1 positive inclusions that are 
observed in a number of mouse models and diseased human tissue. As 
discussed above, chaperone proteins, which are involved in protein folding, as 
well as the UPS, responsible for the degradation of mis-folded and damaged 
proteins, are both closely linked to protein aggregation in neurodegenerative 
diseases such as ALS. MNs, which are selectively affected in ALS, may be 
deficient in their ability to up-regulate chaperones and/or more susceptible to 
disruption of the UPS. I have chosen to investigate further the role of chaperone 
proteins, more specifically sHSPs, in mutant S0D1-linked FALS. A model cell 
system of mutant S0D1 inclusion formation has been established, whereby 
over-expression of G85R mutant S0D1 and subsequent treatment with 
proteasome inhibitor in HEK293 cells leads to inclusion formation. These 
inclusions have been shown, by IMF microscopy, to contain both components of 
the UPS and chaperone proteins. The results are presented in chapter 3. Co-
expression of sHSPs in this model system have been shown to influence G85R 
mutant S0D1 inclusion formation: co-expression of wt sHSPs decreases the 
amount of insoluble mutant SODI , whereas mutant sHSPs further increase the 
amount of insoluble mutant S 0 D 1 . Co-expression of mutant sHSPs increases 
the insolubility of wt S 0 D 1 , which, in this system is soluble under normal 
conditions. The increase in insoluble mutant S0D1 appears to increase the 
viability of these cells. These data are presented and discussed in chapter 4. 
49 
Chapter 5 addresses the in vitro interactions of S0D1 with sHSPs. Three 
different methods have all shown that there is no such interaction. Chapter 6 
addresses parallel studies carried out in a neuronal cell line, Neuro 2a (N2a) 
cells. Such a model cell system is better suited to these studies, as MNs 
undergo selective degeneration in ALS. However, the transfection rate in this 




MATER!ALS AND METHODS 
Chemicals 
All chemicals used were of analytical grade and, unless otherwise stated, 
purchased from either VW R (Lutterworth, UK) or Sigma Aldrich (Poole, UK). 
Cell Culture 
The following cell lines were used: human embryonic kidney (HEK293) cells, 
human lens epithelial (H36CEI) cells, breast cancer (MCF7) cells, human 
astrocytoma (บ373MG) cells, mutant H36CEI (mH36) cells, neuroblastoma X 
spinal cord hybrid (NSC34) cells and mouse neuroblastoma Neuro2A cells. 
HEK293, H36, MCF7, บ373MG and Neuro 2A cells were obtained from the 
European Collection of Cell Cultures (ECACC, Porton Down, UK). mH36 cells 
were obtained from a cataract patient. NSC34 cells were a gift from Professor 
Pam Shaw (University of Sheffield). All cell lines, excluding NSC34 and n2a 
cells, were cultured เท Dulbecco'ร Modified Eagle Medium (DMEM) 
supplemented with 10%(v/v) foetal calf serum (FCS) 2ทาM L-glutamine and 
antibiotics ( 1 0 0 บ т ґ penicillin and ЮОцдтІ'^ streptomycin), at 37°c in a 
humidified atmosphere of 5%(v/v) ՇՕշ. In general, cells were grown in 75 cm^ 
flasks, 9cm diameter culture dishes or 6-well plates (Greiner Bio-One). The cells 
were grown to 80-90% confluence, prior to subculture. Cells were washed twice 
with phosphate buffered saline (PBS) and then 2 ml trypsin-EDTA solution 
(0.05% (พ/v) trypsin, 0.02% (พ/V) EDTA) was added and the cells incubated 
until they had detatched and rounded up; this normally takes approximately 5 
min. The cell suspension was diluted 1:10 with pre-warmed medium, which was 
supplemented with more media so as to cover the bottom of the culture vessel. 
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NSC34 cells were grown as above but were subcultureel at 60-70% confluence 
by trituration with 10ml pre-warmed medium and then seeding new 75 c m 2 
flasks with 1.5x10® cells and adding sufficient pre-warmed media to cover the 
bottom of the flask. Neuro 2A cells were grown as above but cultured in 
Modified Eagle Medium (MEM) supplemented with 10%(v/v) FCS, 2mM L-
glutamine, ImM sodium pyruvate and antibiotics ( ю о и т ґ penicillin and 
ЮОцдтІ'^ streptomycin), 
Cell Transfect ions 
For transient transfections, plasmid DNA was prepared using MaxiPrep kits 
(Qiagen). Samples were then run on agarose gels to check the quality of the 
DNA (see below for an example). 
supercoiled DNA 
1 -wtSOD1pECFP-C1 
2 - G85RSOD1pECFP-C1 
3 - G93ASOD1pECFP֊C1 
2 3 
Cells were seeded onto either 6-พθΙΙ plates or 9 cm diameter culture dishes, 
and at a confluence of ^50%, were transfected with GeneJuice (Novagen), a 
lipid based system. This method involved combining 3μΙ GeneJuice with 100μΙ 
รemm-free (DMEM). This was allowed to stand for 5 min before the adding 
dropwise to 1.5μ9 maxiprep DNA. This solution was incubated at room 
temperature for 15 mln and then added dropwise to the ceils. 
Cells were then grown as described previously for up to 48 hr prior to further 
processing, in the case of proteasome inhibitor treatment, ALLN (N-Acetyl-Leu-
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Leu-Nle-CHO) (Calbiochem), was added to a final concentration of 6.25μฎm「^ 
at specific time intervals following transfection. 
Cell Viability Assays 
Cell viability assays were carried out using CellTiter96 AQueousOne Solution Cell 
Proliferation Assay (Promega), according to the manufacturers instructions. 
This colourmetric assay measures the quantity of formazan, which is directly 
proportional to the number of living cells. 
Cell Extractions 
Cells were washed twice with phosphate buffered PBS.To obtain a total protein 
cell extract, cells were taken up into cell extraction buffer (0.5M Tris-HCI pH8， 
0.5M EDTA, 10%(พ/v) SDS, 1%(v/v) protease inhibitor cocktail). The lysate was 
then boiled for 5 min and dissolved in 2x Laemmli'ร sample buffer (2x LSB) 
(Laemmli, 1970). 
To obtain soluble and insoluble cell fractions, cells were taken up into cell 
homogenisation buffer (3M KCl, 0.01%(v/v) Triton X-100 and 1 %(v/v) protease 
inhibitor cocktail in Tris buffered saline (TBS)). Cell lysates were homogenised 
using a Dounce homogeniser, before centrifugation at 10000 rpm (gav 一 
10600g), for 15 min at 4°c. The pellet fraction (P1) was washed once in TBS 
containing 5mM EDTA before dissolving in 2x LSB. A sample of the supernatant 
(SN) fraction (SN1) was added to an equal volume of 2x LSB and the remainder 
subjected to h igh speed centrifugation; 4 0 0 0 0 rpm (gav 一 1 0 6 0 0 0 g ) зо min at 
4°c in a Beckman TLS55 rotor. This resulted in รN2 and P2; รN2 was added to 
an equal volume of and P2 dissolved in 2x LSB. 
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Prior to addition of 2x LSB, protein concentrations were determined using the 
BCA Protein Assay (Pierce), according to the manufacturers instructions. 
Electrophoresis 
Proteins (between 10 and 50μ9) were separated by SDS-PAGE under reducing 
conditions, essentially as described previously (Laemmli, 1970), using Mini Gel 
equipment (BioRad Mini Protean II). Protein samples were loaded onto 
12%(พ/v) bis-acrylamide gels and run at 200V for approximately 45 min until the 
dye front had reached the bottom. After electrophoresis gels were either stained 
or blotted (see below). 
Coomassie staining: gels were stained for 5-10 min in Coomassie stain 
(0.5%(พ/v) R250 Coomassie brilliant blue, 50%(v/v) methanol, 10%(v/v) acetic 
acid), destained by several changes of destain (10%(v/v) methanol, 5%(v/v) 
acetic acid) and the protein bands visualised and recorded, using a Fujifilm 
LAS-1000 Intelligent Dark Box 11 running IR LAS-1 ООО Pro version 2.11 
software. 
Sypro staining: gels were fixed for 30 min (50%(v/v) ethanol, 10%(v/v) acetic 
acid), stained overnight with Sypro Ruby (Molecular Probes) and then destained 
for 30 min (10% methanol, 7% acetic acid). Gels were then viewed under uv 
light for visualisation and recording (see previous paragraph). 
Western Blott ing 
Western blotting was performed using the semi-dry method as described by 
Kyhse-Anderson, (1984), using a BioRad Trans Blot SD Semi Dry Transfer Cell. 
12%(w/v) Polyacrylamide mini-gels (see section 2.6) were transferred to 
nitrocellulose membranes for 1 hr at — 0 . 8 — M e m b r a n e s were washed in 
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deionised water, stained with Ponceau ร for 5 min and destained with TBS after 
visualisation and recording if necessary. Membranes were then blocked and 
stained using either the BSA or milk method (see below). 
The BSA method; membranes were blocked overnight at 4°c in blocking buffer 
(5% (พ/V) BSA in TTBS (TBS containing 0.2% (v/v) Tween)). Primary and 
secondary antibodies were diluted in 1 % (พ/v) BSA in 1:1 TTBS:TBS and 
incubated for 1 hr at room temperature on a shaking platform. Membranes 
were washed five times, each for 5 min, in TTBS following the primary and TBS 
following the secondary antibody incubation. Antibodies were detected by 
enhanced chemiluminescence (ECL) (Amersham) using a Fujifilm LAS-1000 
Intelligent Dark Box 11 running IR LAS-1000 Pro version 2.11 software.The milk 
method: membranes were blocked overnight at 4°c in blocking buffer (5% (พ/v) 
milk powder (Teseo) in TTBS). Antibodies were diluted in washing/staining 
buffer (3% (พ/v) milk powder in TBS/TTBS (1:1); primary antibodies for 2 hr 
and secondary antibodies for 1 hr, all at 37°c with agitation. After each 
incubation, membranes were washed five times, each for 5 min, in 
washing/staining buffer and antibodies were detected by ECL. Details of the 
primary antibodies used are shown in Table 2.1. Appropriate horseradish 
peroxidase (HRP) conjugated secondary antibodies (Dako) were diluted 
1:1000. 
Immunofluoresence Microscopy 
Cells to be used for IMF microscopy were seeded onto 13 mm glass coverslips 
in 6-well plates or LabTek chamber slides (Nunc). Cells were washed twice with 
PBS and fixed with 4%(พ/v) paraformaldehyde in PBS for 15 min, washed twice 
with PBS containing 0.02%(พ/v) BSA and 0.02%(พ/v) sodium azide 
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(PBS/BSA/NaAz). They were then permeabilised with 0.5%(v/v) Triton X-100 in 
PBS for 5 min at 4°c. After washing twice with PBS/BSA/NaAz, cells were 
incubated with normal goat serum diluted 1:10 in PBS/BSA/NaAz for 20 min. 
Cells were then incubated with primary antibody for 1 hr, washed twice 
(PBS/BSA/NaAz), incubated with secondary antibody and SSngmľ1 DAPI {4',6– 
diamidino-2-phenylindole, dihydrochloride) for 1 hr and washed again 
PBS/BSA/NaAz). All antibodies were diluted in PBS/BSA/NaAz and incubations 
carried out in the dark to prevent bleaching. Primary antibodies (see Table 2.1) 
were detected using either Alexa Fluor594-labelled goat anti-rabbit IgG, Alexa 
Fluor488-labelled goat anti-mouse IgG (appropriately diluted, Molecular Probes) 
or TRITC (tetramethylrhodamine isothiocyanate)-labelled anti-mouse IgG. 
Coverslips were mounted on slides with Citifluor (Citifluor Labs), a fluorescent 
protective reagent and the coverslip, was sealed with clear nail varnish. 
Cells were observed with a Zeiss Axioplan fluorescent microscope using 63X 
Plan-Apochromat 1.4N objective lens or Zeiss Axiovert 200M confocal 
microscope (both Carl Zeiss). Images were obtained via a cooled CCD camera 
(Digital Pixel Ltd) running IP Lab software for the fluorescent microscope and 
LSM 510 META software for the confocal microscope, and processed using 
Adobe Photoshop 8. 
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The Binding Site 
SC35 Mouse 1 :1000 Sigma 
SP10 Mouse 1 :1000 Prescott (Duncee) 
Dorfin Rabbit 1 :100 (Niwa et al., 2001) 
บbiquitin Mouse igGi P4D1 1 :100 Cell Signalling 
Technology 
พ В - Western Blotting, IMF 一 іmmunofluorescence 
Molecular Cloning 
Cloning SODI into pET23b (CN Biosciences): 
SODIpBSKS(-) was used as a template in a PCR reaction (see Table 2.2) with 
the following primers: forward primer 一 5'– 
GTACATATGGCCACGAAGGCCGTGTGCGTGC-3'; reverse primer - 5'– 
GAATTCTTATTGGGCGATCCCAATTACACC-3', in order to introduce an Ndel 
site into the S0D1 construct. The resultant PCR fragment was directly ligated 
into the pTOPO vector system (Promega) according to the manufacturers 
instructions. This system allows blue white selection for insert containing 
colonies. DNA from positive clones was prepared using a Miniprep kit (Qiagen). 
The DNA was digested with Ndel and EcoRI (NEB) and the DNA run on a 1 % 
agarose qel at 90mA for approximately 30 min. The 500bp insert band was cut 
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out under UV transillumination and purified using a QIAquick gel extraction kit 
(Qiagen). This purified insert band was then ligated into pET23b pre-digested 
with the same restriction enzymes (REs) using T4 DNA ligase (Roche). The 
ligation reactions were then transformed into the DH5a strain of E.coli. DNA 
was prepared by miniprep (Qiagen) and restriction analysis with Ndel and 
EcoRI used to confirm the presence of the 500bp insert prior to sending 
samples for full sequencing (University of Durham Sequencing Facility). 
Cloning into pBUD (Invitrogen): 
S0D1pECFP-C1 (prepared previously by Vilius Pigaga, University of Durham) 
was digested with Nhel, blunted by incubation with T4 DNA polymerase 
(BioLine), digested with BamHI and the resultant fragment gel purified. pBUD 
vectors, containing wt or mutant (R120G) aB-crystalllin in the CMV site (cloned 
previously by Terry Gibbons, University of Durham) were digested with Noti, 
blunted by incubation with T4 DNA polymerase (Bioline), digested with Bglll and 
the resultant vector band gel purified. The purified cut vector was then 
dephosphorylated with alkaline phosphatase (Roche) and used in a ligation 
reaction with the S0D1 fragment prior to transformation into the DH5a strain of 
E.coli. DNA was prepared by miniprep (Qiagen) and restriction analysis with 
Stul used to confirm the presence of the 500bp insert prior to sending samples 
for sequencing. 
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Table 2.2 PCR Reaction Condit ions 
Initial melting 94°c for 2 min 
Strand separation 94°c for 1 min 
Primer annealing 66°c for 1 min Extension 72°c for 2min 30s Number of cycles 30 
Final Extension 72°c for 5 min 
Map of pET23b (CN Biosciences) 
2ła(Os«3u«fK«l«Mknarits 
f ļjfomotei 
Т7 Iranscripilon start 
T7»Tag coding sequence 
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The maps for рЬТ-23Ь(+). pET-23c(+) and 
pRT-23di+) are lhe same às, рҒТ гЗа{+) 
(shown) with the fnllowtng exceptions: 
pKT-23bi+) is a 366Sbp plasmid: รนbtroct 
I bp from each site beycttฬ BamH I at 198. 
pET-23c{+) Is a 3664bp ptosmฬ. subtract 
2bp from each slie beyòná Ват}] I at- 1ՑՏ. 
pET-23dţ4-) เร a з ш ь р plasmtđ; the ВатН 1 
slie İs (ท the same readltig frame as In pET-
2 Î C ( + ) . An jVíซ 1 site is subsututed for the 
ЛУр І site with a net Ibp dฟeiion at position 
zae of pET-23ci+). As a resulü jMľo I cuts 
pET-23d(+) at 234. and iVAe 1 CUÍS at 229. 
For lite lest of the sites, suturaci 3b|> frtMB 
each she t>eyoíKl position 239 til pET-23a(+). 
j\He I docs fiot c u i ļ)ET-23(H+). Note also 





В Й 1 น ) 7 I t n ř S i 
59 










Coimnentร foi' рВш1СЕ4Л 
4595 nacleottdes 
CMV promoter: bascs 7-594 քվիք ļ 
CMV Forward piiiïùng site: bases 544-564 
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CMV multiple cloiùaa site; bascs 664-713 
fítyc epitope: bลSCS 719-748 
öxHis tag: bascs 764-782 
SV40 poíyadcnylaňon sequence: bases 803-933 
Zeocüi resistance gene: bases 1063-1437 (con^leiiieiitaiy รท-and) 
EM7 promofer: bas« 1456-1:510 (compicinentary strand) 
SV40 early promoter: bases 1547-1869 (coraplcmcntaiy strand) 
EF-Ια promoter: bascs 1885-305Î 
ЕҒ- Ια Fonvarđ priming site: bascs 2999-3019 
EF-і α multiple cioningsiîe: bases 3062-3126 
V5 epitope: bases 3127-316ร 
бхНіร่ tag: bases з!78-3195 
BGH Reverse piímittg site: bas€ร 3218-3235 (complementary stianđ) 
BGH polyadcùylatìon sequcHC с ： baies 3224-3447 







Expression of Recombinant S0D1 
SOD1pET23b vectors were transformed into the BL21(DE3)plysS strain of 
E.co//. Single colonies were picked and grown overnight at 37°c with vigorous 
shaking at 225 rpm in a starter culture of 10ml LB broth containing 2μΜ ՇսՇ\շ 
and ZnCİ2 and antibiotics (бОцдтГ^ ampicilin and 34цдт1"^ chloramphenicol). 
The starter culture was diluted 1:100 in a 1 I culture and this was grown at 37°c 
with ฟgoro니s shaking at 225 rpm until the absorbance at 600nm (Абоо) reached 
0.25-0.5. Plasmid expression was then induced with 0.5mM IPTG 
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(isopropylthio-ß-D-galactosidase) and the culture grown for a further 4 hr at 
37°c with vigorous shaking. Cells were then harvested by centrifugation at 5000 
rpm (gav - 6 0 0 0 g ) , for 15 min at 4°c in a Beckman J L A 8 . 1 0 0 0 rotor. The 
supernatant (SN) was removed and the pellet stored at -20°c for subsequent 
purification. 
Purif ication of Recombinant S0D1 
For purification of soluble S 0 D 1 , the pellet was freeze-thawed (-20°c and room 
temperature) two to three times, resuspended in 20ml TEN buffer (50mM 
TrisHCI pH8, 1mM EDTA, ЮОтМ NaCI, 1mM MgCİ2,, 0.2M PMSF) containing 
Complete protease inhibitor cocktail tablet (Roche) and homogenised in a 
Dounce homogeniser. Benzonase nuclease (Novagen) was added at a 
concentration of 10บml'^ to the lysate and incubated at room temperature for 30 
min. This was then centrifuged at 15000 rpm (gav 一 27000g) in a Beckman JA-
20 rotor for ЗО min at 4°c. Polyethyleneimine (PEI) was added to form ล 0.06% 
(v/v) solution, followed by incubation on ice for 5 min and centrifugation at 
15000 rpm for 10 min in order to pellet the DNA. The SN was dialysed overnight 
against buffer A (20mM TrisHCI pH8.5, 20mM NaCI, 1mM MgCİ2,, 1mM EDTA, 
1mM DTT, 0.2M PMSF), centrifuged at 50000 rpm (Qav 一 128000g) for 30 min 
at 4°c in a Beckman MLA-80 rotor and loaded onto a TMAE-sepharose column 
(VWR), pre-equilibrated with buffer A. Protein was eluted with a linear gradient 
of 0-1M NaCI in buffer A. Fractions were collected and SODI positive fractions, 
as determined by SDS-PAGE and Coomassie staining, were pooled and stored 
at -20°c. 
For purification of insoluble S0D1 from inclusion bodies, the bacterial pellet 
was resuspended in 10ml lysis buffer (0.75M sucrose, 50mM TrisHCI pH8, 
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1 т М EDTA) and the solution homogenised using a Dounce homogeniser. 1 ml 
of lysozyme (Imgml ՜ 1 ) was then added and the suspension incubated on ice 
for 30 min. 20 ml detergent buffer ( 1 % (พ/v) deoxycholic acid, 1 % (v/v) 
Nonident P40， 20mM TrisHCI pH7.5, 2mM EDTA, 0.2M NaCI) was then added, 
the lysate homogenised using a Dounce homogeniser and centrifuged at 15000 
rpm (gav 一 27000g) for 15 min at 4°c in a Beckman JA-20 rotor. The pellet was 
resuspended in 20 mi buffer AB ( 1 % (v/v) Triton X-100, 5mM EDTA, 1.5M KCl, 
Ю т М TrisHCI р Н 8 ) and centrifuged at 1 0 0 0 0 rpm (gav 一 1 2 0 0 0 g ) for 5 min at 
4°c. The pellet was resuspended in 20 ml buffer AB and stirred for 10 min prior 
to centrifugation at 10000 rpm for 20 min at 4°c. The pellet was then 
resuspended in 20 ml buffer с ( Ю т М TrisHCI pH8, 0.15M NaCI, 5mM EDTA) 
and centrifugecl at 10000 rpm for 5 min at 4°c. 
The pellet was then dissolved in chromatography buffer A (6M urea, 20mM 
TrisHCI pH8.5, 1mM DTT, 2mM EDTA), dialysed over night at 4°c against the 
same buffer and centrifuged at 50000 rpm (gav 一 128000g) for зо min at 4°c in 
the Вөскат MLA-80 rotor. The supernatant was loaded onto a TMAE-
sepharose column pre-equilibrated with chromatography buffer A and eluted 
with a linear gradient of 0-1M NaCI in the same buffer. Fractions were collected 
and SOD1 positive fractions, as determined by SDS-PAGE and Coomassie 
staining, were pooled and stored at -20°c. 
The anion-exchange chromatography system used was a Merck-Hitachi 
Biochromatography system, controlled by Chromeleon system (Dionex). 
Immunoprecipitat ion 
For IP experiments, 10μ9 of each protein was made up to 50μΙ with buffer A 
(150mM KCl, 20mM K3PO4). Proteins were mixed together (as appropriate) 
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and incubated at room temperature for 1 hr. 10μΙ of purified monoclonal аВ-
crystallin antibody was added and the mixture mixed continuously for 1-2 hr. 
50μΙ of pre-cleaned and pre-blocked protein G-coupled beads was added and 
the mixture rotated end-over-end for 1 hr. The protein G slurry was washed 4 
times with PBS, each time removing the SN with a syringe and 23 gauge 
needle. After the fourth wash, 50μΙ 2x LSB was added to the beads and the 
mixture boiled for 5 min. The SN was removed and samples analysed by SDS-
PAGE and Western Blotting. 
Size-Exclusion Chromatography 
A Fractogel EMD BioSEC 650 column (VWR) pre-equilibrated with buffer A 
(100Mm NaCI, 20mM TrisHCI pH8, 2μΜ CuCİ2 and ZnCİ2,1mM DTT) containing 
Complete protease inhibitor cocktail tablet (Roche). Protein samples were 
dialysed overnight at 4°c against the same buffer, centrifuged at 50000 rpm (gav 
- 128000g) for зо min at 4°c in a Beckman MLA-80 rotor, treated as 
appropriate and loaded onto the column. Fractions were collected and analysed 
by SDS-PAGE and Sypro staining. 
The size-exclusion chromatography (SEC) system used was a Merck-Hitachi 
Biochromatography system, controlled by Chromeleon software (Dionex). 
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CHAPTER З 
ESTABLISHING A MODEL CELL SYSTEM OF MUTANT SOD INCLUSION 
FORMATION AND PROPERTIES OF INCLUSIONS FORMED 
Mutant SOD inclusion formation in culture cells 
In order to investigate the role of sHSPs in mutant S0D1 inclusion formation, 
we first had to establish a model cell system of mutant S0D1 inclusion 
formation. In order to do this, preliminary experiments were carried out in which 
HEK293 cells, and H36CEI cells cartying an aB-crystallin mutation (known as 
mH36 cells), were transiently transfected with mammalian expression vectors 
containing yellow fluorescent protein (YFP)-tagged and non-tagged wt and 
mutant S0D1 (see Materials and Methods for details of transfection protocol 
and construction of vectors). Cell extracts were taken from these cells and 
samples analysed by SDS-PAGE and Western Blotting. In mH36 cells, transient 
transfection of wt and G85R mutant S0D1 did not cause an increase in SODI 
levels, whereas transient transfection of the same constructs which were YFP-
tagged, did give rise to increased SODI levels (Figure 3.1 A). Similar results 
were seen with HEK293 cells after over-expression of 6 different mutant tagged 
and non-tagged constructs (Figure 3.1 B). It was decided to continue the studies 
using the YFP-tagged constructs, as they resulted in over-expression of wt and 
mutant SODİS. It may have been that the non-tagged S0D1 constructs did 
result in over-expression, but at levels which could not be detected by Western 
Blotting. 
Since establishing that YFP-tagged S0D1 constructs could be 
successfully over-expressed in these cell lines, more studies were carried out in 
order to visualise and determine the appropriate conditions for mutant S0D1 
aggregation and inclusion formation. Johnston et al., (2000), have previously 
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shown that over-expression of mutant S0D1 in HEK293 cells and subsequent 
treatment with proteasome inhibitor led to SOD aggregation and inclusion 
formation. HEK293 and mH36 cells were transiently transfected with mutant 
YFP-tagged SODI s and grown in the presence of proteasome inhibitor 
{6.25μgm\՜^ ALLN), prior to processing for IMF microscopy studies (see 
Materials and Methods). Under these conditions, mutant, but not wt S0D1 
formed inclusions in both cell types. The results are shown in Figure 3.2. These 
mutant S0D1 inclusions appeared as intense green juxtanuclear accumulations 
of protein. In HEK293 cells, 14% of transfected cells contained inclusions, in 
mH36 cells, 2 1 % of transfected cells formed inclusions. 
These preliminary studies have demonstrated that YFP-tagged S0D1 
constructs can be successfully over-expressed in HEK293 and mH36 cells, and 
IMF microscopy has shown that this over-expression, in the presence of 
proteasome inhibitor, leads to mutant S0D1 inclusion formation in HEK293 and 
mH36 cells. During these studies, 6 different mutant S0D1 constructs were 
used and each showed similar successful over-expression and inclusion 
formation in culture cells. It was decided that for subsequent studies, one 
mutant construct, namely G85R, be used. G85R mutant SODI has decreased 
activity in humans compared to other FALS mutants (Borchelt et al., 1994, 
(Bowling et al., 1995). Bruijn et al., (1997b), report that G85R mutant SODI 
caused dominantly inherited, rapidly progressing disease in mice, in spite of low 
levels of accumulated protein. Also, due to good transfection rates (>50%) in 
HEK cells, this cell line was used as our model cell system of G85R mutant 
SODI inclusion formation. 
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Endogenous chaperone levels affect mutant S0D1 inclusion formation 
It was interesting to note, that compared to HEK293 cells, there was an 
increased proportion of G85R mutant SODI-transfected mH36 cells which 
contained inclusions. 2 1 % of transfected mH36 cells contained inclusions 
whereas 14% of HEK293 cells contained inclusions. In each experiment, two 
hundred transfected cells were counted, and scored for the presence/absence 
of an inclusion, and experiments were carried out in triplicate. Our criterion for 
the presence of an inclusion was an intense green juxtanuclear accumulation, 
rather than a small green spot (see Figure 3.2D for examples of each). This 
difference in inclusion frequency may have been due to the mutation in аВ-
crystallin this cell line carries. This suggests that mutant S0D1 inclusion 
formation is affected by levels of functional aB-crystallin. Chaperone proteins 
such as aB-crystallin help prevent mis-folded proteins from damaging cells, as 
described previously. It is possible that the mutation in aB-crystallin in this cell 
line renders the cells less efficient at processing mutant SOD and thus leading 
to increased inclusion formation. This led us to hypothesise that endogenous 
chaperone levels may affect mutant S0D1 inclusion formation. To study this 
further, บ373 and MCF7 cells were transiently transfected with YFP-tagged 
mutant S0D1 and treated with proteasome inhibitor, as before. Subsequent IMF 
microscopy showed the incidence of aggregation and inclusion formation in 
these cell lines was lower than previously seen with HEK293 and mH36 cells: 
either no inclusions were observed or the beginnings of small aggregations 
were observed infrequently (Figure 3.3). The levels of chaperones in each cell 
type appear to relate to the number of inclusions: บ373 cells contain high levels 
of both aB-crystallin and HSP 27, and MCF7 cells contain high levels of HSP 
27, but no aB-crystallin (Figure 3.3). The high levels of these two chaperones in 
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the บ373 cells could explain the lack of inclusions and in the case of MCF7 
cells, the high levels of HSP 27 probably compensate for the lack of аВ-
crystallin, again explaining the lack of inclusions. HEK293 cells contain low 
levels of both of proteins and although mH36 cells contain slightly higher levels 
compared to the HEK293 cells, (Figure 3.3), some of the aB-crystallin is 
mutated and thus non-functional. These results support our hypothesis that 
endogenous chaperone levels influence mutant SODI inclusion formation. 
Accumulat ion of protein folding and protein degradation machinery at 
mutant S0D1 inclusion sites 
If endogenous chaperoneร influence mutant S0D1 inclusion formation, it is 
possible that they may be involved directly, and localise to the inclusions. G85R 
mutant S0D1 inclusions were formed in HEK293 cells as described previously, 
and IMF confocal microscopy shows that aB-crystallin, HSP 27 and HSP 70 all 
co-localise to these cytoplasmic inclusions (Figure 3.4). 
The UPS acts to degrade un- or mis-folded and damaged proteins and 
dysfunction of the UPS is often seen in neurodegenerative diseases. The target 
for degradation of such proteins by the UPS is polyubiquitin and in ALS patients 
and mouse models, inclusions have been shown to contain Ub (Shibata et al., 
1996 and Bruijn et al., 1998). With our model cell system of G85R mutant S0D1 
inclusion formation, we have shown, using IMF confocal microscopy, that Ub is 
co-localised to these mutant S0D1 inclusions (Figure 3.5A). Dorfin, another 
component of the UPS, an E3 Ub ligase, has been shown to be up-regulated in 
ALS (Ishigaki et al., 2002), and its over-expression prevents cell death induced 
by mutant protein (Niwa et al., 2002). Again, using our HEK293 cell system and 
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IMF confocal microscopy, we show that dorfin co-localises to G85R mutant 
S0D1 inclusions (Figure 3.5B). 
These studies confirm previous reports of accumulation of both 
chaperone proteins; the protein folding machinery, and UPS components; the 
protein degradation machinery, into mutant S0D1 inclusions. 
Affects of mutant S0D1 on transcript ion 
Although over-expression of mutant S0D1 in cultured MNs leads to inclusion 
formation and cell death (Durham et al., 1997), it is not certain how mutant 
S0D1 exerts its toxicity. In other neurodegenerative diseases, mutant protein 
has been shown to affect transcription, which may contribute to 
neurodegeneration. It is possible mutant S0D1 may have a similar role in ALS. 
We have antibodies to components of the speckle compartments, which have 
been used to see if transcription is altered in response to G85R mutant SODI 
over-expression. Huntingtin is the protein which causes Huntington's Disease 
when its polyglutamine tract is extended above thirty-seven glutamine residues. 
Truncated N-terminal mutant huntingtin represses transcription, whereas wt 
huntingtin does not (Kegel et al., 2002). These authors suggest that wt 
huntingtin has a function in the nucleus in the assembly of nuclear matrix bound 
protein complexes involved in transcriptional repression and pre-mRNA splicing, 
and that proteolysis of mutant huntingtin may inappropriately repress 
transcription in Huntington's Disease, ß-amyloid precursor protein (APP), as its 
name suggests, is the precursor of the amyloid-ß-peptide, which makes up the 
plaques seen in brains of Alzheimer's Disease patients. Muresan and Muresan, 
(2004), showed that a phosphorylated, C-terminal fragment of APP is present in 
the nucleus and localises to the splicing factor compartnienf, thus indicating that 
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APP may have a role in pre-mRNA splicing and/or transcription in Alzheimer's 
Disease. 
Speckles, or interchromatin granules, are distinct nuclear structures 
involved in the processing and transcription of RNA (Wei et al., 1999). They can 
be detected using antibodies to components of the spliceosome, either small 
nuclear ribonucleoprotein (snRNP) components like Sm and UIA, or non-
snRNP components like SC35 and TMG (Antóniou et al., 1993). By looking at 
the pattern of speckles obtained by staining with these antibodies, insights into 
the transcriptional activity of the cell can be gleaned. Using our HEK293 model 
cell system, we used antibodies to SC35 and Sm to look at speckle patterns. 
HEK293 cells were grown on coverslips, and transiently transfected, with 
appropriate S0D1 constructs, prior to fixing and staining with these antibodies, 
and IMF confocal microscopy. Results are shown in Figure 3.6. No differences 
in the speckle patterns were observed between control (mock transfected), wt, 
G85R SODI or proteasome inhibitor only treatments. These results suggest 
that mutant S0D1 does not have any affect on the transcriptional activity of the 
cell. Whether this is a general phenomenon or specific for the G85R mutant of 
S0D1 used here remains to be ascertained. However, there are disadvantages 
of using speckles as a measure of transcription, as speckles indicate gross 
transcriptional changes. It is possible that mutant S0D1 affects transcription on 
a smaller scale. An alternative method of investigating this affect would be to 
monitor differential gene expression in the presence and absence of mutant 
S0D1 using DNA microarrayร, for example. 
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Conclusions 
SODI inclusions are a histopathological feature of ALS: intracytoplasmic S 0 D 1 -
containing inclusions are observed in mutant S0D1 transgenic mice (Bruijn et 
al., 1998), as well as ALS patients (Shibata et al., 1996). We have established a 
model cell system of G85R mutant SODI inclusion formation. Over-expression 
of YFP-tagged G85R mutant S0D1 in HEK293 cells and treatment with 
р rotéaseme inhibitor, gives rise to mutant S0D1 inclusion formation. These 
inclusions contain both chaperone proteins and the UPS components dorfin and 
Ub, but do not appear to effect transcription. Previous studies have implicated 
chaperone proteins and the UPS in neurodegenerative diseases such as ALS. 
For example, Bruening et al., (1999), have shown that over-expression of HSP 
70 decreased the number of cultured cells containing mutant S0D1 inclusions 
as well as prolonging cell survival and a report by Niwa et al., (2002), showed 
that over-expression of dorfin prevented cell death caused by mutant protein. 
Our results further support the role of chaperones, as we have shown 
endogenous chaperone levels influence inclusion formation. We shall use this 
model cell system to further study the role of chaperone proteins, or more 
specifically, small heat shock proteins (sHSPs), in mutant S0D1 inclusion 
formation. 
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Figure 3.1 A Over-expression of S0D1 in mH36 cells 
The figure shows total protein extracts from mH36 cells over-expressing S0D1 
constructs, run on a 12% (พ/v) Polyacrylamide gel, blotted and probed with a 
monoclonal anti-SODI antibody. Lanes 1 and 2 show controls: lane 1 - non-
transfected cells, lane 2 - cells transfected with YFP-tag only. Lane 3 - cells 
transfected with wt YFP-tagged S 0 D 1 , lane 4 - cells transfected with G85R 
YFP-tagged SODI , lane 5 - cells transfected with wt SODI and lane 6 - cells 
transfected with G85R SODI . เท lane з there is a faint band corresponding to 
over-expression of wt YFP-tagged S0D1 . The fact that the wt construct appears 
to express less well than the mutant could be due to contamination of the DNA 
in that particular preparation. Alternatively, it could be the case that the amount 
of protein loaded onto the gel was inaccurate. 
Figure 3.1 В Over-expression of S0D1 in HEK293 cells 
The figure shows total protein extracts from HEK293 cells over-expressing 
various S0D1 constructs, again run on a 12% (พ/v) Polyacrylamide gel, blotted 
and probed with an anti-SODI antibody. Lanes 1 and 2 are controls: lane 1 -
non-transfected cells and lane 2 - YFP-tag only transfected cells. Lanes 3 to 7 
show cells transfected with tagged constructs and lanes 8 to 12 show cells 
transfected with non-tagged constructs. Lanes 3 and 8 - A4V SODI , lanes 4 
and 9 - G37R SODI , lanes 5 and 10 - G85R SODI , lanes 6 and 11 - G93A 
S0D1 and lanes 7 and 12 - I113T S 0 D 1 . The lower molecular weight bands 
seen in lanes 4 to 7 could be proteolytic fragments. To confirm loading 
consistencies, a ß-actin antibody stain could have been used. 
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Figure 3.2 Mutant S0D1 inclusion formation 
Mutant, but not wt S 0 D 1 , forms inclusions in mH36 and HEK293 cells in 
response to over-expression and proteasome inhibition, achieved by addition of 
6.25цдт1'^ ALLN. Figure 3.2A shows over-expression of wt S0D1 in mH36 
cells. Figure 3.2B shows over-expression of four different mutant SODI s in 
тНЗб cells. 1 - G37R, շ - G85R, з - G93A and 4 - I113T. YFP-tagged SODI is 
green, vimentin is stained red. Figure 3.2C shows over-expression of wt SODI 
and figure 3.2D shows over-expression of G85R S 0 D 1 , our chosen mutant, in 
HEK293 cells. YFP-tagged SODI is shown เท green. Non-transfected cells 
showed no green signal (data not shown). In Figure 3.2D, the arrows indicate 
intense green juxtanuclear accumulations of protein counted as inclusions as 



































Figure 3.3 Endogenous chaperone levels affect G85R mutant SOD 
inclusion format ion 
Cell type %of transfected cells containing 
inclusions 
HEK293 1 4 ± 2 
MH36 21 ±1 .7^^ 
MCF7 0 
บ373 0 





Figure 3.3 Endogenous chaperone levels affect G85R mutant S0D1 
inclusion formation 
The table shows the percentage of transfected cells containing inclusions for 
each cell type used. Cells were transiently transfected with G85R mutant S0D1 ， 
treated with proteasome inhibitor and processed for IMF microscopy studies. 
Two hundred transfected cells were counted and scored for the 
presence/absence of an inclusion in each experiment, and experiments were 
carried out in triplicate. Our criteria for the presence of an inclusion was an 
intense green juxtanuclear accumulation rather than a small green spot (see 
Figure 3.2D for examples of each). 
The image shows the different levels of various chaperone proteins in the cell 
types used. Cells extracts were taken and protein concentrations measured 
using the BCA protein assay (see Materials and Methods). Equal amounts of 
each sample were loaded, subjected to SDS-PAGE on 12% (พ/v) 
Polyacrylamide gels and Western Blotted with the appropriate antibody. Key: с 
一 antibody positive control; н 一 HEK293 cell extract; ทา 一 тНЗб cell extract; M -
MCF7 cell extract and บ - บ373 cell extract. 
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Figure 3.4 Heat shock proteins co-localise with G85R mutant SODI 
inclusions 
HEK293 cells were seeded onto coversl ips, transiently transfected with 
appropriate constructs, and treated with proteasome inhibitor to induce inclusion 
formation, prior to fixing and staining with appropriate antibodies for IMF 
confocal microscopy. A - aB-crystall in staining in red. в 一 HSP 27 staining in 
red. С 一 HSP 70 staining in red. In all cases mutant YFP-tagged S 0 D 1 is green, 
but appears yel low due to co-localisation. The nuclei were visualised by staining 








Figure 3.5 Accumulation of UPS components with G85R mutant S0D1 
inclusions 
HEK293 cells were seeded onto coverslips, transiently transfected with 
appropriate constructs, and treated with proteasome inhibitor (ALLN) to induce 
inclusion formation, prior to fixing and staining with appropriate antibodies for 
IMF confocal microscopy. Figure 3.5A 一 co-localisation of Ub to mutant S 0 D 1 
inclusions; 1 - 3 wt SOD, 4 - 6 G85R S O D I . Figure 3.5B - co-localisation of 
dorfin to mutant SOD inclusions; 1 - 3 wt S 0 D 1 , 4 - 6 G85R S O D I . YFP-tagged 
S 0 D 1 is green and the UPS component ¡S stained red. 
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Figure 3.6 The speckle pattern in HEK293 cells is not affected by over-
expression of mutant S0D1 
HEK293 cells were seeded onto coverslips and transiently transfected with 
appropriate constructs, prior to fixing and staining with appropriate antibodies 
for IMF confocal microscopy. Figure 3.6A 一 SC35 antibody; 1 - untreated cells, 
2 - ALLN only treated cells, 3 and 4 - wt S 0 D 1 , 5 and 6 - G85R S O D I · Figure 
3.6B - Sm antibody; 1 - untreated cells, 2 一 ALLN only treated cells, 3 and 4 -
wt S 0 D 1 , 5 and 6 - G85R S 0 D 1 . YFP-tagged S O D I is green, speckle 


















CHAPERONE PROTEIN INVOLVEMENT IN MUTANT SODI INCLUSION 
FORMATION 
The aim of this study was to investigate the involvement of chaperone proteins, 
specifically sHSPs, in mutant S O D I inclusion format ion. HSP 70 protects 
against mutant S 0 D 1 inclusion formation and subsequent cell death in cultured 
primary MNs (Durham et al., 1997), and HSP 70 and 40 protect against mutant 
S 0 D 1 inclusion formation and cell death in a neuroblastoma cell line, as well as 
improving neu rite out-growth, this being diminished in cells containing mutant 
S 0 D 1 inclusions (Takeuchi et al., 2002). Together with the demonstrat ion that 
mutant S 0 D 1 is co-immunoprecipi tated with chaperone proteins, namely HSP 
70, 40 and aB-crystal l in, f rom NIH3T3 cell extracts (Shinder et al., 2001)， this 
shows that chaperone proteins help to prevent inclusion formation, possibly by 
direct interaction with the proteins involved. Data obtained from preliminary 
experiments, described in the previous chapter, would also support a role for 
chaperone proteins in inclusion formation. It was shown that endogenous sHSP 
levels influenced G85R mutant S 0 D 1 inclusion formation. 
A model system of G85R mutant S 0 D 1 inclusion formation in HEK293 
cells was establ ished, as described in chapter 3. The formation of mutant S 0 D 1 
inclusions was fol lowed biochemically. Twenty-four hours after transient 
transfection of G85R mutant S 0 D 1 into НЕК cells and treatment with 
proteasome inhibitor, cell extracts were prepared. These cell extracts were then 
separated into soluble and insoluble fractions as described in Materials and 
Methods. Firstly, the extracts were centr i fuged at low speed resulting in a 
soluble supernatant (SN1) and insoluble pellet (P1). Secondly, a sample of SN1 
was centr i fuged at high speed resulting in a soluble supernatant (รN2) and 
79 
insoluble pellet (P2). P1 , resulting f rom the low speed centrifugation, will contain 
cytoskeletal components and associated material, as well as nuclear fragments. 
P2, resulting f rom the high speed centrifugation, will contain other insoluble 
material, such as the insoluble mutant S 0 D 1 compris ing the inclusions. These 
four fractions were then analysed by SDS-PAGE and Western blotting using a 
monoclonal ant i -S0D1 antibody. Therefore, the proportion of mutant S 0 D 1 in 
the insoluble P2 fraction, or the proportion of mutant S 0 D 1 present in 
inclusions, can be monitored under different condit ions. 
If wt S 0 D 1 was over-expressed, S 0 D 1 was soluble; S 0 D 1 
immunoreact ive bands were present in the SN but not р fractions (Figure 4.1A). 
This is consistent with results from IMF microscopy which showed that over-
expression of wt S 0 D 1 and treatment with р rotéaseme inhibitor did not result in 
inclusion formation (see Figure 3.2) When G85R mutant S 0 D 1 was over-
expressed, a proportion of S 0 D 1 was insoluble; S 0 D 1 immunoreact ive bands 
were present in both the SN and р fractions (Figure 4.1 B). Again, this is 
consistent with IMF microscopy, which showed that over-expression of G85R 
mutant S 0 D 1 and treatment with proteasome inhibitor resulted in mutant S 0 D 1 
inclusion formation (Figure 3.2). 
In order to study the involvement of sHSPs in inclusion formation, it was 
decided to investigate the effects of co-expression of sHSPs on the proportion 
of mutant S 0 D 1 in the insoluble fraction. 
Co-expression of S0D1 and (xB-crystallin using pBUD 
Initially, it was decided to co-express S 0 D 1 and the sHSP, aB-crystal l in, using 
a mammal ian expression vector (pBUD) with two multiple cloning sites (MCSs). 
For these experiments, several pBUD vectors were cloned by insertion of either 
80 
wt or G85R mutant S O D I , and wt or R120G aB-crystal l in into each of the 
MCSs. Expression vectors were constructed as described in Materials and 
Methods. In order to test whether expression of both proteins from these 
constructs was occurring, they were transiently transfected into HEK293 cells, 
and treated with the proteasome inhibitor ALLN to induce inclusion formation. 
However, IMF microscopy studies revealed that S 0 D 1 and aB-crystal l in were 
not being simultaneously expressed within the cell (see Figure 4.2), and hence 
the vectors were not functioning as expected. In order to overcome this problem 
and continue with the studies, we decided to achieve co-expression of S 0 D 1 
and aB-crystal l in by transfection of two separate vectors. 
Effects of sHSPs on insoluble G85R mutant S0D1 levels in HEK293 cells 
Due to the problems encountered with the pBUD expression system, co-
expression of S 0 D 1 and sHSP was carried out using two separate vectors. 
Cells were transfected, treated and extracts prepared and processed as 
described above. Over-expression of both aB-crystal l in and HSP 27, both 
sHSPs, resulted in a decrease in the proport ion of insoluble G85R mutant 
S 0 D 1 in these cells. Transfections were carried out in triplicate and 
representative blots are shown in Figure 4.3 (A, в and C). Quantif ication of the 
Western Blots using OptiQuant Imaging software al lowed the amount of 
insoluble S 0 D 1 , as a percentage of the total transfected S 0 D 1 , to be 
calculated. For G85R mutant S 0 D 1 alone, 22 .4% 士 0.01 of the transfected 
mutant S 0 D 1 was present in the pellet fractions, i.e. insoluble. Over-expression 
of aB-crystall in resulted in a decrease in the amount of insoluble mutant S 0 D 1 ， 
as evidenced by the absence of S 0 D 1 immunoreact ive bands in the pellet 
fractions. Over-expression of HSP 27 decreased the amount of insoluble mutant 
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S O D I to 4 .5% ±0.6. To confirm that both vectors were being successfully over-
expressed in each case, samples were analysed by SDS-PAGE and Western 
blotting using either anti aB-crystal l in or anti HSP 27 antibodies. The results 
shown in Figure 4.3 (D and E) show that this is indeed the case. เท summary, 
over-expression of sHSPs decreased the amount of insoluble mutant S 0 D 1 and 
consequently decreased mutant S 0 D 1 inclusions in this HEK293 cell system. 
Mutant sHSPs: are they involved in ALS? 
Two recent reports have implicated mutant sHSPs in diseases related to ALS. 
Mutations in HSP 27 have been linked to CMT disease and distal hereditary 
motor neuropathy, and neuronal cells transfected with mutated HSP 27 showed 
a reduced viability when compared to cells expressing wt protein (Evgrafov et 
al., 2004). Similarly, mutations in HSP 22 have been identified in families with 
distal hereditary motor neuropathies and cultured cells transfected with mutated 
HSP 22 formed intracellular inclusions (Irobi et al., 2004). The residues which 
are mutated in these sHSPs; K141 in HSP 22 and 8135 in HSP 27, are 
conserved residues located in the core a-crystall in domain and hence disrupt 
protein structure. Is it possible, therefore, that over-expression of mutant sHSPs 
in our model cell system might have a similar affect and exacerbate the 
proportion of insoluble mutant S 0 D 1 . 
Experiments were carried out as described previously, but this t ime the 
sHSPs that were co-expressed carried mutations, namely R120G aB-crystal l in, 
ร 1 3 5 F and R140G HSP 27. R120G aB-crystal l in is the mutation which has 
been linked to DRM (Perng et al., 1999b) and ร 1 3 5 F HSP27 has been linked to 
CM丁 disease and distal hereditary motor neuropathy, as described above. 
Indeed, as shown in Figure 4.4, the presence of these sHSP mutants within the 
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cell gave rise to increased amounts of insoluble S 0 D 1 . Again, using OptiQuant 
Imaging software, co-expression of R120G aB-crystal l in increased the amount 
of insoluble mutant S 0 D 1 from 22 .4% 土 0.01 to 31 .8% ± 1.0. In the case of 
ร 1 3 5 F and R140G HSP 27， the amount of insoluble S O D I was increased from 
22 .4% ± 0.01 to 30 .9% ± 0.4 and 37.3% ± 0.4, respectively. 
Thus, sHSPs carrying mutations further exacerbate insoluble mutant 
S 0 D 1 inclusion formation in this HEK293 cell system. This raises the question 
as to whether these proteins merely add to the insult on the cell which is already 
compromised by the presence of mutant S 0 D 1 ， or whether they are exerting an 
affect by themselves? To provide insights into this, we co-expressed these 
mutant sHSPs with wt S O D I . If over-expressed, even in the presence of 
proteasome inhibitor, wt S O D I is soluble and no inclusions are formed. 
Consequently, any affects resulting f rom the co-expression of mutant sHSPs 
would be apparent fol lowing the preparation and analysis of the soluble and 
insoluble cell extracts, as described above. Over-expression of R120G aB-
crystallin with wt S 0 D 1 increased the amount of insoluble material by 15.3% 土 
0.8. In the case of S135F and R140G HSP 27， these values were 15.3% ± 0.5 
and 12.2% 土 0.2， respectively. The Western Blots are shown in Figure 4.5. 
Therefore, these data suggest that mutations in sHSPs result in the formation of 
inclusions by S 0 D 1 , which is soluble under normal condit ions. It could be 
possible, however, that this affect is not specific for S O D I , but is a general 
affect of the mutant sHSPs. This has not been addressed in this instance, but is 
an interesting matter for further investigation. 
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Viability of HEK293 cells in the presence and absence of wt and mutant 
sHSPs 
What affect do these mutant S 0 D 1 inclusions have on the cells in which they 
are present? Do they, for example, affect cell viability? Durham et al., (1997) 
and Takeuchi et al., (2002), have demonstrated that mutant S 0 D 1 inclusions do 
affect cell viability, both in cultured primary MNs and a neuroblastoma cell line. 
Here, we used a cell viability assay kit (see Materials and Methods) to assay 
HEK293 cell viability in the presence and absence of mutant S 0 D 1 and mutant 
S 0 D 1 inclusions. The effects of expression of wt and mutant sHSPs on cell 
viability were also assessed. The results are shown in Figure 4.6. Over-
expression of wt S 0 D 1 and G85R mutant S 0 D 1 had no effect on cell viability. 
However, mutant S O D I inclusion formation, induced by over-expression of 
G85R mutant S 0 D 1 and subsequent proteasome inhibition, reduced cell 
viability by approximately 50%. This was significantly different f rom cells treated 
with proteasome inhibitor only (p<0.001). When mutant S 0 D 1 was co-
expressed, in the presence of proteasome inhibitor, with aB-crystal l in and HSP 
27, cell viability was not significantly affected. Similar f indings were obtained 
when mutant sHSPs were co-expressed; cell viability was not significantly 
affected. 
In conclusion, mutant S 0 D 1 , in the presence of the proteasome inhibitor 
ALLN, resulted in a decrease in HBく293 cell viability. From the IMF studies 
described in chapter 3, over-expression of mutant S 0 D 1 in the presence of 
ALLN caused inclusion formation, so it can be assumed that mutant S 0 D 1 
inclusion formation leads to a decrease in HEK293 cell viability. Co-expression 
of sHSPs, whether wt or mutant, does not significantly affect cell viability. 
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Conclusions and discussion 
It has been shown that over-expression of G85R mutant S 0 D 1 in HEK293 cells, 
and subsequent proteasomal inhibition results in the formation of mutant S 0 D 1 
inclusions. It has also been shown that this process is affected by sHSPs: ocB-
crystallin and HSP 27 decrease the amount of insoluble mutant S 0 D 1 and thus 
act to prevent mutant S 0 D 1 inclusion formation. Mutation of these proteins 
abolishes these affects and in fact makes the situation worse; their presence 
coincides with increases in insoluble mutant S 0 D 1 and consequently mutant 
S 0 D 1 inclusion formation. Results from the cell viability studies show that over-
expression of mutant S 0 D 1 and proteasomal inhibition, corresponding to 
mutant S 0 D 1 inclusion formation, caused a decrease in HEK293 cell viability. 
Under these condit ions, co-expression of wt and mutant sHSPs did not appear 
to significantly effect viability. 
It remains to be determined whether these effects or wt sHSPs will be of 
benefit in ALS treatment. A report by Kieran et al., (2004), has shown that up-
regulation of HSPs, by using a co-inducer of the heat shock response, 
increases life expectancy in a mouse model of ALS. However, this report did not 
discuss the mechanisms by which this HSP up-regulation exerts its effects. 
There is still some controversy as to whether inclusions are formed as a 
protective mechanism in order to sequester soluble, toxic proteins, or whether it 
is the inclusions themselves that are toxic, due to sequestrat ion of other cellular 
proteins or disruption of cellular pathways and responses. To some extent, this 
appears to be disease dependent. For example, Lewy bodies in Parkinson's 
disease are thought to have a causative role in the disease, whereas nuclear 
inclusions in polyglutamine diseases are thought to be protective (reviewed by 
Tran and Miller, 1999). Although reports by Bruening et al., (1997) and 
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Takeuchi et al., (2002) suggest that mutant S 0 D 1 inclusion formation causes 
cell death, a study by Lee et al., (2002) showed that the number of cells with 
mutant S 0 D 1 inclusions, and the inclusion burden per cell had no significant 
effect on cell viability and that increased cell viability was not linked to a 
decrease in inclusions. 
Co-expression of wt sHSPs decreases the amount of insoluble mutant 
S 0 D 1 , which in turn, does not significantly affect cell viability. The mutations in 
aB-crystall in and HSP 27 result in their inability to fold correctly and as a 
consequence cause them to become more prone to aggregat ion themselves. 
This indirectly leads to loss of function (Perng et al., 1999b; Chavez Zobel et al., 
2003). Although co-expression of such mis-folded proteins with mutant S 0 D 1 
causes further increases in insoluble mutant S 0 D 1 , this does not significantly 
effect cell viability. 
Another interesting finding is that, in this model cell system, mutant 
sHSPs cause a normally soluble protein (wt S O D I ) to aggregate. It is not 
known whether this is specific for S 0 D 1 ， or whether these mutant sHSPs would 
have a similar effect on other soluble proteins. Mutations in HSP 22 and 27 
have been linked to other neurodegenerat ive diseases (Irobi et al., 2004 and 
Evgrafov et al., 2004). Is it possible that sHSPs are also mutated in ALS? The 
exact mechanisms by which mutant S 0 D 1 exerts its effects in ALS disease 
pathogenesis remain to be determined. It may be possible that in some cases, 
mutations which render the protein folding machinery defective, play a role. 
What about the vast majority of ALS cases that are not linked to mutations in 
S 0 D 1 ? Are mutations in сһарөгопе proteins seen here? Presently, all these 
questions remain unanswered, but studies designed to address them will be 
important. 
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F igure 4.1 Mutant , bu t no t w t S 0 D 1 , is i nso lub le 
A 
В 
SN1 P1 ร N 2 P2 
HEK293 cells were transiently transfected with wt or G85R mutant S 0 D 1 and 
treated with 6.25цдтГ^ ALLN to induce inclusion format ion. Twenty-four hours 
after transfection, the cells were harvested and cell extracts prepared. These 
were then subjected to a series of centrifugation steps to obtain soluble and 
insoluble fractions (see Materials and Methods for detai ls). These fractions were 
run on 1 2 % (พ/v) Polyacrylamide gels and analysed for the presence of S 0 D 1 
by Western blotting using an an t i -S0D1 antibody. (A) Fractions f rom cells 
transfected with wt S 0 D 1 , (B) Fractions from cells transfected with G85R 
mutant S O D I . Key: SN1 - supernatant 1; P1 - pellet 1 (both from the low 
speed centrifugation step); ร N 2 - supernatant 2; P2 一 pellet 2 (both from the 
high speed centrifugation step). In the case of both wt and mutant fractions, 
SOD1 is soluble: S 0 D 1 is present in the two supernatant fractions. However, in 
the case of the mutant fraction, some of the S 0 D 1 is insoluble and 
consequent ly detected in the pellet fractions. 
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Figure 4. 2 C o - e x p r e s s i o n of G85R m u t a n t S 0 D 1 a n d a B - c r y s t a l l i n u s i n g 
t he p B U D e x p r e s s i o n vec to r 
To study the effects of sHSPs on mutant S 0 D 1 inclusion formation, we used a 
mammal ian expression vector, pBUD, with two multiple cloning sites, for 
simultaneous expression of two different proteins. A pBUD vector containing 
both G85R S 0 D 1 and aB-crystal l in was c loned, and transiently transfected into 
our HEK293 cell system, as described in Materials and Methods. Cells were 
treated with proteasome inhibitor and processed for IMF microscopy. A-D show 
cells containing YFP-tagged G85R mutant SOD and E-H show the same cells 
stained for aB-crystal l in. This panel of images shows that some cells express 
one protein, but not the other (C and G, D and H), thus demonstrat ing that the 
pBUD vector was not functioning correctly. In other cases, one cell may show 
expression of both proteins at comparable levels, whereas another cell shows 
similar expression of one protein and decreased expression of the other (A and 
E， В and F). For this reason, subsequent transfections were carried out using 
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SN1 P1 ร N 2 P2 
SN1 P1 ร N 2 P2 SN1 P I ร N 2 P2 
G85R G85R + sHSP 
HEK293 cells were transiently transfected with G85R mutant S O D I together 
with either aB-crystal l in or HSP 27 and soluble and insoluble extracts prepared, 
as descr ibed previously. These fractions were run on 1 2 % (พ/v) Polyacrylamide 
gels and analysed for the presence of S 0 D 1 by Western blotting using an anti-
S 0 D 1 antibody. The figure shows that co-expression of sHSPs results in a 
decrease in the amount of insoluble S 0 D 1 , as indicated by the decreased 
intensity of the pellet fractions in the presence of sHSPs. (A) G85R mutant 
S 0 D 1 only. (B) G85R mutant S 0 D 1 and aB-crystal l in. (C) G85R mutant S 0 D 1 
and HSP 27. To confirm that both vectors were being successful ly over-
expressed, these fractions were run on 12% gels and Western blotted using anti 
aB-crystal l in or anti HSP 27 antibodies. (D) shows successful over-expression 
of aB-crystal l in compared to controls and (E) shows successful over-expression 
of HSP 27 compared to controls. Key: SN1 ― supernatant 1 ; P I — pellet 1 (both 
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prepared by the low speed centri fugation step); ร N 2 一 supernatant 2; P2 
pellet 2 (both prepared by the high speed centrifugation step). 
Tab le 4.1 
Percen tage of m u t a n t S 0 D 1 in pel le t f r a c t i o n s 
P1 P2 Total Р 
A 7.4 ± 0 . 5 15 ± 0 . 4 22.4 ± 0 . 1 
В 0 0 0 
С 0 4.5 ± 0 . 6 4 .5±0 .6 
Table 4.1 shows the amount of mutant S 0 D 1 in each of the pellet fractions, as 
a percentage of total S 0 D 1 , for each cell treatment. (A) G85R mutant S O D I 
only. (B) G85R mutant S 0 D 1 and aB-crystal l in. (C) G85R mutant S 0 D 1 and 
HSP 27. P1 - pellet 1, P2 — pellet 2 and total р - total pellet material. 
90 
Figure 4.4 Mu tan t sHSPs fu r the r i nc rease the a m o u n t of i n s o l u b l e G85R 





SN1 P1 ร N 2 P2 
HEK293 cells were transiently transfected with G85R mutant S O D I together 
with either R120G mutant aB-crystal l in, S135F or R140G mutant HSP 27. 
Soluble and insoluble extracts were prepared after 24 hr, as descr ibed 
previously. These fractions were run on 12% (พ/v) Polyacrylamide gels and 
analysed for the presence of S 0 D 1 by Western blotting using an an t i -S0D1 
antibody. The figure shows that co-expression of mutant sHSPs further 
increases the amount of insoluble S O D I , as indicated by the increased intensity 
of the pellet fractions in the presence of mutant sHSPs. (A) G85R mutant S 0 D 1 
only. (B) G85R mutant S 0 D 1 and R120G aB-crystal l in. (C) G85R mutant S 0 D 1 
and ร 1 3 5 F HSP 27. (D) G85R mutant S O D I and R140G HSP 27. Key: SN1 -
supernatant 1; P1 - pellet 1 (both prepared from the low speed centrifugation 
step); ร N 2 一 supernatant 2; P2 一 pellet 2 (both prepared f rom the high speed 
centrifugation step). 
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Tab le 4.2 
Percen tage of m u t a n t S 0 D 1 in pel le t f r ac t i ons 
P1 P2 Total Р 
A 7.4 ± 0 . 5 15 ± 0 . 4 22.4 土 0.05 
В 2 1 . 8 ^ ^ 10 土 3 1 . 8 ^ ^ 
С 22.7 ± 0.7 8.1 ± 1 . 1 30.7 土 0.4 
D 7.9 ± 0 . 8 29.4 ± 0 . 4 37.3 ± 0 . 5 
Table 4.2 shows the amount of mutant S O D I in each of the pellet fractions, as 
a percentage of total S 0 D 1 , for each cell treatment. (A) G85R mutant S 0 D 1 
only. (B) G85R mutant S 0 D 1 and R120G aB-crystal l in. (C) G85R mutant S 0 D 1 
and ร 1 3 5 F HSP 27. (D) G85R mutant S O D I and R140G HSP 27. P1 一 pellet 1， 
P2 一 pellet 2 and total р 一 total pellet material. 
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F igure 4.5 Mutan t s H S P s a f fec t t he so lub i l i t y o f w t S O D I 
SN1 P1 ร N 2 P2 
HEK293 cells were transiently transfected with wt S 0 D 1 together with either 
R120G mutant aB-crystal l in, ร 1 3 5 F or R140G mutant HSP 27. Soluble and 
insoluble extracts were prepared after twenty-four hr， as descr ibed previously. 
These fractions were run on 12% (พ/v) Polyacrylamide gels and analysed for 
the presence of S 0 D 1 by Western blotting using an an t i -S0D1 antibody. The 
results show that normally, wt S 0 D 1 is soluble. However, the presence of 
mutant sHSPs affects the solubility of this wt S 0 D 1 : in their presence, some of 
the S 0 D 1 is shifted into the insoluble fraction. (A) wt S 0 D 1 only. (B) wt S 0 D 1 
and R120G aB-crystal i in. (C) wt S 0 D 1 and S135F HSP 27. (D) wt S 0 D 1 and 
R140G HSP 27. Key: SN1 一 supernatant 1; P I - pellet 1 (both prepared from 
the low speed centrifugation step); ร N 2 一 supernatant 2; P2 一 pellet 2 (both 
prepared from the high speed centrifugation step). 
Tab le 4.3 
Percen tage of m u t a n t S 0 D 1 ๒ pel le t f r a c t i o n s 
P1 P2 Total Р 
A 0 0 0 
В 11.9 ± 0 . 5 3.4 ± 0 . 4 15.3 土 0.8 
С б 15.3 ± 0 . 5 
Đ 0 12.2 ± 0 . 2 1 2 г 2 ± 0 . 2 
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Table 4.3 shows the amount of mutant S 0 D 1 in each of the pellet fractions, as 
a percentage of total S 0 D 1 , for each cell t reatment. (A) wt S 0 D 1 only. (B) wt 
S 0 D 1 and R120G aB-crystal l in. (C) wt S 0 D 1 and ร 1 3 5 F HSP 27. (D) wt S O D I 
and R140G HSP 27. P1 ― pellet 1, P2 - pellet 2 and total р - total pellet 
material. 
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Figure 4.6 The e f f ec t s of sHSPs o n t he v iab i l i t y o f m u t a n t S 0 D 1 i n c l u s i o n 
c o n t a i n i n g HEK293 ce l l s 
The figure shows the cell viability of HEK293 cells containing G85R mutant 
S 0 D 1 inclusions, in the presence and absence of wt and mutant sHSPs. Cells 
were transiently transfected with the appropriate S 0 D 1 constructs and cell 
viability assays carried out after twenty-four hours, as descr ibed in Materials 
and Methods. The results shown are the mean values 土 SD. Over-expression of 
wt S 0 D 1 and G85R mutant S O D I had no effect on cell viability. However, 
mutant S 0 D 1 inclusion formation, induced by over-expression of G85R mutant 
S O D I and subsequent р rotéaseme inhibition, reduced cell viability by 
approximately 5 0 % . This was significantly different f rom cells treated with 
proteasome inhibitor only (p<0.001). When mutant S 0 D 1 was co-expressed, in 
the presence of proteasome inhibitor, with aB-crystal l in and HSP 27， cell 
viability was not significantly affected. Similar f indings were obtained when 
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CHAPTER 5 
S O D I เท vitro INTERACTIONS STUDIES 
The aim of this project is to investigate the role of sHSPs in mutant S 0 D 1 
inclusion format ion. As well as carrying out these studies in our model cell 
system, the in vitro interactions of S O D I with sHSPs can also be studied. 
C o p p e r a n d z inc are requ i red fo r bac ter ia l e x p r e s s i o n of S 0 D 1 
In order to study S 0 D 1 interactions in vitro, it was first necessary to produce 
recombinant S 0 D 1 . Wild-type (wt) S 0 D 1 was cloned into the pET23b vector 
(see Materials and Methods section 2.9). Once this was completed, small scale 
bacterial inductions were set up to ascertain the best condit ions for expression 
of wt S 0 D 1 . BL21(DE3)plysS were transformed with the р ET vector and ล 
single colony used to inoculate a starter culture. Then a 50ml culture was grown 
to the log phase of growth and the bacteria induced with 0.5mM IPTG. Samples 
were taken before induction and at 1 hr intervals for the next 3 hr and samples 
analysed on 12% (พ/v) SDS-PAGE gels with Coomassie Blue staining. The 
results are shown in Figure 5,1 A. Al though it is clear f rom this that there was an 
increase in the amount of one of the proteins over t ime, re-running of the gel 
and Western Blotting, using a monoclonal S 0 D 1 antibody showed that this 
protein was not S O D I (Figure 5.1B), as S 0 D 1 was present at similar levels, 
both before and after induction. This may be due to the codon usage for 
arginine in the S 0 D 1 construct. BL21(DE3)plysS have preference for specific 
arginine codons. Rosetta cells, another strain of E.coli which can be used for 
bacterial expression, have different arginine codon preferences and were used 
to try and overcome this problem. The experiment was repeated using Rosetta 
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cells, but the results (Figure 5.1С) show that there was no induction of any 
protein. 
S 0 D 1 is a metal loenzyme, which requires both copper and zinc ions as 
co-factors. Maybe a lack of these metal ions in the growth media was causing 
this deficiency in bacterial expression. 2μΜ copper and zinc sulphate were 
added to the growth media and used to culture BL21(DE3)plysS. The growth of 
these cells in the presence and absence of copper and zinc sulphate was 
monitored and no dif ferences were observed. The induction experiments 
descr ibed above were then carried out using BL21(DE3)plysS, grown in the 
presence of copper and zinc ions. These condit ions al lowed successful 
induction of wt S 0 D 1 , as shown by SDS-PAGE and Coomassie staining and 
conf i rmed by Western Blotting (Figure 5.1D). 
Recombinant wt S 0 D 1 was purif ied as insoluble material f rom inclusion 
bodies and also as soluble protein. Insoluble S 0 D 1 was purified f rom the 
bacterial pellet as described in Materials and Methods, and eluted on a 
Fractogel EMD BioSEC 650 column, using a linear gradient of 0-1M NaCI in 6M 
urea buffer. Eluate fractions were col lected and the S 0 D 1 positive fractions 
determined by SDS-PAGE and Coomassie staining and pooled. The results are 
shown in Figure 5.2A. For soluble S 0 D 1 , the purif ication was carried out as 
descr ibed in Materials and Methods and eluted on a T M A E sepharose column 
using a gradient of 0-1M NaCI in a 20mM TrisHCI buffer. Again, eluate fractions 
were col lected and the S 0 D 1 positive fractions determined by SDS-PAGE and 
Coomassie staining and pooled. The results are shown in f igure 5.2B. 
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I n te rac t ion of r e c o m b i n a n t S O D I w i t h a B - c r y s t a l l i n : i m m u n o p r e c i p i t a t i o n 
s t u d i e s 
After the successful purif ication of recombinant wt S 0 D 1 f rom the bacterial 
expression system, as both soluble and insoluble protein, in vitro experiments 
were set up to determine whether S 0 D 1 interacts with aB-crystal l in. As well as 
wt S 0 D 1 , three different mutants were also used, namely G37R, G85R and 
G93A. These were kind gifts f rom Lawrence Hayward (University of 
Massachusetts) . aB-crystal l in was kindly provided by Ming Pemg (University of 
Durham). Initially, IP experiments were set up. 10μ9 each of S O D I (wt or 
mutant) and aB-crystal l in were incubated at room temperature for 1 hr prior to 
addit ion of a monoclonal aB-crystal l in ant ibody for the precipitation step, as 
descr ibed in Materials and Methods. SDS-PAGE on 1 2 % (พ/v) gels and 
Western Blotting, using a polyclonal SOD antibody, were used to analyse the 
samples. The results are shown in Figure 5.3. Figure 5.ЗА shows that S 0 D 1 ， 
both wt and the two mutants (G85R and G93A), interact with aB-crystall in in 
vitro. Samples f rom IP using a monoclonal aB-crystal l in ant ibody contain S O D I , 
as shown by Western Blotting with a polyclonal S 0 D 1 antibody. Figure 5.3B, 
however, shows results f rom a control experiment, in which the IP step was 
omit ted. Here, the same results were obtained, indicating that S 0 D 1 interacts 
with the protein G-coupled beads and thus the interaction seen in Figure 5.ЗА is 
not a specific interaction. 
I n te rac t i on of r e c o m b i n a n t S 0 D 1 w i t h aB-crys ta l l iทะ s ize e x c l u s i o n 
c h r o m a t o g r a p h y s t u d i e s 
The results f rom the IP experiments were inconclusive due to an artificial 
interaction between S 0 D 1 and the protein G-coupled beads themselves. 
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Another method of investigating interactions between two proteins is by using 
SEC. This method is based on the retention t ime of large and small particles 
passing through a column. Large particles pass through with a short retention 
t ime, whereas smaller ones have a longer retention t ime, due to adsorption by 
the column material. If two proteins interact, a shift in particle size occurs, 
reflected by a shift in retention t ime. W e used this method, as described in 
Materials and Methods, to see if S 0 D 1 interacts with. aB-crystal l in. wt S 0 D 1 
and 3 mutant S O D İ S were used in these studies. The SEC traces obtained for 
both wt and mutant S O D I were the same, whether in the presence or absence 
of aB-crystal l in (Figure5.4). This suggests that neither wt nor mutant S 0 D 1 
interacts with aB-crystal l in. This was somewhat unexpected, given the results 
obtained using our model cell system, which showed that sHSPs including a B -
crystallin co-localise with mutant S 0 D 1 and have a role in increasing its 
solubility. 
I n te rac t ion of r e c o m b i n a n t S 0 D 1 w i t h a B - c r y s t a l l i n : B iaco re s tud ies 
One last method was used to study the possible interaction between S 0 D 1 and 
aB-crystal l in. The Biacore chip system is available in our department. The 
Biacore system monitors biomolecular interactions on the surface of a sensor 
chip. One molecule, in this case aB-crystal l in, is immobil ised on the surface of 
the chip, whilst the other molecule(ร), in this case the wt and mutant S 0 D 1 , are 
injected in a cont inuous flow over the surface of the chip. Changes in the mass 
concentrat ion at the surface, which indicate interactions, are then monitored. 
Using this system, we show that there is no interaction between aB-ctystal l in 
and either wt or mutant S 0 D 1 . These studies were carried out at several 
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different temperatures, including the physiological temperature of 37°c. These 
data are consistent with those obtained using SEC. 
C o n c l u s i o n s 
W e have used two independent methods to study the possible interaction of 
both wt and mutant S O D I with aB-crystal l in, and both have shown that both wt 
and mutant S O D I do not interact with aB-crystal l in in vitro, even at 37°c. This 
is somewhat unexpected, given the results obtained using our model cell 
system, which show that sHSPs including aB-crystal l in co-localise with mutant 
S 0 D 1 and have a role เท increasing its solubility. It is possible that the 
interaction occurring in situ in the HEK293 cell system is not a direct interaction, 
but one involving other proteins. This may explain why no interaction was 
observed between S 0 D 1 and aB-crystal l in in vitro. This is unlikely, however, as 
a report by Shinder et al. , (2001), showed co-immunoprecipi tat ion of mutant 
S 0 D 1 with HSP 70, 40 and aB-crystal l in. It is possible that the two methods 
used here were not best suited to these types of studies and that other methods 
of studying in vitro interactions may have yielded different results. Also, the 
S 0 D 1 used in these in vitro studies was in a soluble form, and it would also be 
of interest to investigate possible interactions between aggregated insoluble 
S O D I and aB-crystal l in. Unfortunately this was not possible in the t ime 
available. 
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в 1 2 3 
BL21(DE3)plysS were transformed with a pET23 vector containing a wt S O D I 
construct. A single colony was used to inoculate a starter culture and this used 
to inoculate a 50ml culture. At the log phase of growth, the bacteria were 
induced with 0 .5mM IPTG. Samples were taken before induction and at 1hr 
intervals over the next 3 hr, before analysis on 1 2 % SDS-PAGE gels with 
Coomassie staining. The gel in (A) shows induction of a protein of 
approximately 20kDa, a similar size to S 0 D 1 (17kDa). W h e n two samples were 
re-run and Western blotted (before and 3 hr after induction), however, the 
amounts of S O D I in each were shown to be similar (B)， indicating that the 
induced protein was not actually S O D I . 
Key: В 一 before induction, 1 - I h r after induction, 2 - 2hr after induction and 3 -
3hr after induction. 
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Figure 5.1 С Bacterial induction of S0D1 in Rosetta cells 
В 1 2 3 
A bacterial induction was set up using Rosetta cells. These cells were 
transformed with a wt S O D I containing pET vector. A single colony was used to 
inoculate a starter culture and this used to inoculate a 50ml culture. At the log 
phase of growth, the bacteria were induced with 0 .5mM IPTG. Samples were 
taken before induction and then after induction at 1 hr intervals for 3 hr. These 
samples were analysed by 1 2 % SDS-PAGE and Coomassie staining, as 
shown. This f igure shows that no protein induction occurred under these 
condit ions. 
Key: В - before induction, 1 - 1hr after induction, 2 一 2hr after induction and 3 ֊ 
3hr after induction. 
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M В շ 
А bacterial induction was set up, using BL21(DE3)plysS grown in media 
containing 2μΜ copper and zinc sulphate. These cells were transformed with a 
wt S 0 D 1 containing pET vector. A single colony was used to inoculate a starter 
culture and this used to inoculate a 50ml culture. At the log phase of growth, the 
bacteria were induced with 0.5mM IPTG. Samples were taken before induction 
and then after induction at 1 hr intervals for 3 hr. These samples were analysed 
by 12% SDS-PAGE and Coomassie staining. As shown in (D), the amount of a 
protein, approximately 17kDa, increases over t ime after induction. Two samples 
were re-run (before and 3 hr after induction), and Western blotting using an ant i-
S 0 D 1 antibody conf i rmed that this protein was indeed S 0 D 1 (E). 
Key: В 一 before induction, 1 - I h r after induction, 2 一 2hr after induction and 3 一 
3hr after induction. M 一 molecular weight in kD. 
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Figure 5.2A Purification of insoluble S0D1 
15.6 
M eluate fractions 
The fractions eluted from the T M A E column, used to purify insoluble S 0 D 1 f rom 
inclusion bod ies, were analysed by SDS-PAGE on 15% gels and visualised by 
Coomassie staining. As shown here, some of the fractions were S 0 D 1 posit ive, 
and these were pooled for use in subsequent in vitro studies. M 一 bovine S O D 
marker, 15.6kDa. 
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Figure 5.2В Purification of soluble S0D1 
15.6 
eluate fractions 
The fractions eluted from the T M A E column, used to purify soluble S 0 D 1 f rom 
the bacterial expression system, were analysed by SDS-PAGE on 15% gels, 
with Coomassie staining. As shown here, some of the fractions were S 0 D 1 
posit ive, and these were pooled and for use in subsequent in vitro studies. M -
bovine S 0 D 1 marker, 15.6kDa. 
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Figure 5.3 Immunoprecipitation results 
(A) 
G93A G85R wt 
(B) 
G93A G85R wt 
This f igure shows results f rom IP experiments. The IP was carr ied out as 
descr ibed in Materials and Methods section 2.12. Samples were analysed by 
SDS-PAGE and Western Blotting, using a polyclonal S 0 D 1 antibody. (A) shows 
that wt, G85R and G93A mutant S 0 D 1 all interact with aB-crystal l in, as in each 
case S 0 D 1 is present in the immunoprecipi tated material . (B), however, shows 
the results of the control experiment, in which the IP step was omit ted. S 0 D 1 , 
both wt and mutant, is still present, indicating that S 0 D 1 interacts non-
specifically with the protein G-coupled beads. 
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Figure 5.4A shows the SEC trace obtained for wt S 0 D 1 . The retention t ime of 
wt S 0 D 1 is approximately 11 min. This is the same as for G85R mutant S 0 D 1 
(figure 5.4B) and the other mutants. The small peak at 15min for the G85R 
mutant S 0 D 1 trace is a component of the buffer. Figure 5.4C shows the trace 
obtained for aB-crystal l in. The peak at 8min is the aB-crystal l in and the later 
peak at 15min is unexpected, likely due to contaminat ion. When S O D I ， whether 
wt or mutant, is mixed with aB-crystal l in, no interaction occurs. Figure 5.4D 
shows an aB-crystal l in peak with an unchanged retention t ime of 8min and the 
wt S 0 D 1 peak also has an unchanged retention t ime of 11min. Figure 5.4E 
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shows an aB-crystal l in peak with an unchanged retention t ime of 8min and the 
G85R mutant S 0 D 1 peak also has an unchanged retention t ime of 11 min. If 
these proteins were interacting, a change in size would occur, resulting in a shift 
in retention t ime. 
NB - the traces for the other two mutants, G37R and G93A, are not shown 
here, but in each case are the same as for G85R mutant S 0 D 1 . 
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CHAPTER 6 
PARALLEL STUDIES IN NEURONAL CELLS 
The results presented here have shown that sHSPs influence mutant S 0 D 1 
inclusion formation in a HEK293 cell model system. Al though mutant S O D I 
inclusions are observed in MNs and astrocytes of G85R mutant S O D I 
transgenic mice (Bruijn et al . , 1998) and in spinal cord samples from FALS 
patients (Shibta et al . , 1996), it is MNs that undergo selective degenerat ion 
during disease progression. A neuronal cell model system would, therefore, be 
more appropriate to study sHSP involvement in mutant S 0 D 1 l inked-FALS. 
Thus, parallel studies were carried out in a murine neuroblastoma cell l ine: 
Neuro 2a (N2a) cells. Mutant S 0 D 1 inclusion formation was induced in these 
cells and the insoluble S 0 D 1 analysed biochemically. The data obtained was 
then compared to that obtained using the HEK293 cell system, and possible 
insights into the selective vulnerabil ity of MNs determined. 
Initially, N2a cells were transiently transfected with either YFP-tagged wt 
or G85R mutant S 0 D 1 and processed for subsequent IMF microscopy, as 
descr ibed in Materials and Methods. Figure 6.1 shows a representative confocal 
image of N2a cells transfected with YFP-tagged G85R mutant S 0 D 1 . Propidium 
iodide was used to stain the nuclei. The image shows that over-expression of 
G85R mutant S 0 D 1 alone did not result in mutant S 0 D 1 inclusion format ion. 
This result was the same as that obtained for HEK293 cells. Figure 6.1 also 
shows that the transfection rate was low. In HEK293 cells, mutant S 0 D 1 
inclusion formation was induced by the addit ion of the proteasome inhibitor 
ALLN to cells over-expressing mutant S 0 D 1 . Accordingly, ALLN was also used 
to try and induce mutant S 0 D 1 inclusion formation in N2a cells. A ränge of 
dif ferent ALLN concentrat ions was used, including the same concentrat ion 
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(6.25цдт1'^) as that used to induce inclusion format ion in HEK293 cel ls. 
However, at a concentrat ion of З ц д т ґ , the N2a cells appeared to be more 
susceptible to the joint stresses of mutant S 0 D 1 over-expression and 
proteasome inhibition, as they washed off the slides during processing. 
However, as shown in Figure 6.2, this concentrat ion of ALLN was sufficient to 
induce inclusion formation in N2a cells over-expressing YFP-tagged G85R 
mutant S 0 D 1 . 
To study the effects of sHSPs on insoluble mutant S 0 D 1 , YFP-tagged 
G85R mutant S 0 D 1 was over-expressed and inclusion format ion induced with 
ALLN, as descr ibed above. Twenty-four hrs after transfect ion, cell extracts were 
prepared and processed into soluble and insoluble fract ions, as descr ibed in 
Material and Methods. However, biochemical analysis could not be carried out 
as the level of transfected S 0 D 1 in these cell extracts was too low and could 
not be detected by Western blotting. As shown by the cell images in Figures 6.1 
and 6.2 this was most likely due to the low transfection rate in this cell line. 
An alternative method for determining the effects of sHSPs on mutant 
S 0 D 1 inclusion formation in N2a cells is IMF microscopy. Al though the 
transfect ion rate was low, it has been shown, none the less, that mutant S O D I 
inclusion formation can be induced. Cells can then be scored for presence, or 
absence of inclusions under different experimental condit ions. N2a cells were 
seeded onto chamber slides and transiently transfected with YFP-tagged G85R 
mutant S 0 D 1 using GeneJuice, as described in Materials and Methods. 
Inclusion format ion induced by the addit ion of Зμgm\^՜՝ ALLN 6hrร after 
transfect ion. Twenty-four hr after transfect ion, the cells were processed for 
subsequent IMF microscopy, as descr ibed in Materials and Methods. It was 
p lanned that cells could then be scored for the presence or absence of mutant 
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S O D I inclusions. Unfortunately, these exper iments were difficult to carry out. A 
large proport ion of the cells were either rounded up, or detatched f rom the 
surface of the slide, which lead to ambiguity in the assigning of inclusions to 
cells. Also, as ment ioned previously, a proport ion of the cells washed off the 
slide surface during processing for IMF microscopy. This detachment could 
possibly bias the results obtained through such analysis, as it would be logical 
to suppose that those cells containing higher levels of transfected S 0 D 1 are the 
most susceptible to do this. However, one observat ion made during this 
microscopic analysis was that the appearance of the S O D I inclusions appeared 
to be different in the presence of sHSPs. The montage in Figure 6.3 shows 
examples of the different phenotypes of mutant S 0 D 1 inclusions in N2a cells in 
the presence and absence of both aB-crystal l in and HSP 27. In the absence of 
sHSPs, the inclusions are dense, tight structures, whereas in the presence of 
the sHSPs, they appear to be much more diffuse. Results publ ished in a report 
by Takeuchi et al. , (2002) support this observat ion. They showed that the over-
expression of HSPs 70 and 40 in N2a cells changed the appearance of mutant 
S O D I inclusions such that they became diffuse throughout the cytoplasm. 
These results would support our f indings in the HEK293 cell system. Here, it 
was shown by biochemical analysis, that over-expression of wt sHSPs 
decreased the proportion of mutant insoluble S 0 D 1 . If there were less mutant 
insoluble S 0 D 1 present within a cell, then it might be expected that the 
inclusion phenotype would become more diffuse. 
The results f rom these N2a cell studies suggest that sHSPs decrease the 
amount of insoluble mutant S O D I . This supports our previous f indings f rom the 
HEK293 cell model . The low transfect ion rates ruled out any biochemical 
analysis of insoluble mutant S 0 D 1 within the cell but it has been shown that 
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over-expression of sHSPs changes the phenotype of mutant S 0 D 1 inclusions, 
causing them to appear more diffusely distr ibuted throughout the cytoplasm, as 
opposed to over-expression of mutant S 0 D 1 alone, where inclusions appear as 
intense green structures. 
If extra t ime had been available, it would have been of interest to use 
alternative neuronal cell l ines or primary neuronal cultures in order to study the 
role of sHSPs in mutant S O D I inclusion format ion. The N2a cells, due to their 
low transfection rate and susceptibil i ty to washing off the slides during IMF 
microscopy processing, were not a good model system. The N2a cells were 
transfected using GeneJuice, as descr ibed in Materials and Methods. One way 
to overcome this low transfection rate would be to use a viral transfect ion 
system, but it is possible that other neuronal cells would be easier to transfect. 
The ability to carry out biochemical analyses in neuronal cells would al low a 
direct compar ison with the results obtained f rom the HEK293 cell system. At 
present, the results presented in this chapter support those f rom the HEK293 
cell system, but more extensive studies on the role of sHSPs in mutant S 0 D 1 
inclusion formation in neuronal cells is required before any meaningful 
conclusions can be reached. 
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Figure 6.1 Over-expression of YFP-tagged G85R S0D1 in N2a cells 
The figure shows two representative confocal images of N2a cells t ransfected 
with YFP-tagged G85R mutant S 0 D 1 . N2a cells were seeded onto chamber 
slides and transiently transfected with this mutant S 0 D 1 construct. Twenty- four 
hrs fol lowing transfect ion, the cells were fixed and stained with propidium iodide 





Figure 6.2 Proteasomal inhibiton induces inclusions in N2a cells over-
expressing YFP-tagged G85R mutant S0D1 
The proteasome inhibitor ALLN was used to induce inclusion formation in N2a 
cells over-expressing YFP-tagged G85R mutant S 0 D 1 . Cells were seeded onto 
chamber slides and transiently transfected with this mutant S 0 D 1 . Six hr after 
transfection, cells were treated with Зцдт І ' ^ ALLN. After a further 18 hr in 
culture, the cells were f ixed and stained with propidium iodide (red) to visual ise 









Figure 6.3 Over-expression of sHSPs changes the appearance of mutant 
S0D1 inclusions in N2a cells 
The figure shows that when mutant S0D1 and sHSPs are co-expressed in N2a 
cells, the appearance of the inclusions changes. (A) Shows that over-
expression of mutant S0D1 resultsin dense inclusions, whereas in (B-C) and 
(D-E), co-expression of aB-crystallin or HSP 27， respectively, changes the 
appearance of the inclusions to a diffuse pattern distributed throughout the 
cytoplasm. N2a cells were seeded onto chamber slides, transiently transfected 
with YFP-tagged G85R mutant SODI , and either aB-crystallin of HSP 27. After 
6 hr the cells were treated with ЗцдтГ^ ALL'N to induce mutant S0D1 inclusion 
formation. After a further 18 hr in culture, the cells were fixed and stained, using 
















ALS is a debilitating neurodegenerative disease, the most common adult onset 
motor neurone disease. The motor neurone diseases are a group of disorders 
affecting MNs. The primary pathogenic processes underlying ALS are currently 
unknown, but it is probable that multiple factors contribute to the disease 
mechanism. A number of major hypotheses have been postulated to explain 
disease progression, including cytoskeletal abnormalities (Xu et al., 1993, Cote 
et al., 1993), excitotoxicty (Rothstein et al., 1992, Shaw et al., 1994) and protein 
aggregation (Deng et al., 1993, Shibata et al., 1996, Durham et al., 1997). A 
number of these contributing factors have been discussed in the introduction. 
The work presented in this study has concentrated on the role of protein 
aggregation in ALS. 
Protein aggregates or inclusions are a common feature of many 
neurodegenerative diseases, including Parkinson's, polyglutamine diseases 
such as Huntington's, SBMA and ALS. The process of aggregate or inclusion 
formation has been characterised (Johnston et al., 1998). They proposed that 
inclusion formation (S a general cellular response to the accumulation of un-
degraded or aggregated protein, which occurs when the capacity of the 
proteasomal degradation machinery, (the UPS), is saturated. They also 
proposed that once formed, these inclusions are delivered, by retrograde 
transport on MTs, to an Ub containing structure at the MTOC. Here, they are 
ensheathed in IF protein and the resultant aggregates are called aggresomes. 
Whether protein inclusions are toxic, or whether they act as a 'sink', protecting 
the cefi against toxic Soluble intermediates, iš ān area of controversy in this 
field. To some extent, it appears to be disease specific (reviewed by Tran and 
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Miller, 1999). Lewy bodies in Parkinson's Disease (intracytoplasmic inclusions 
with a dense eosinophilic core and pale surrounding halo) are thought to have a 
causative role เท the disease, whereas nuclear inclusions observed in 
Huntington's Disease are thought to have a protective role (Arrásate et al., 
2004). 
In ALS, inclusions are thought to contribute to neu rodegeneration. 
Twenty percent of FALS cases are linked to mutations in S0D1 . These 
mutations may cause S0D1 to mis-fold and thus render it more prone to 
aggregation, resulting in the formation of toxic inclusions. Mutations in S0D1 
occur throughout all five exons, suggestive of altered protein conformation; X-
ray crystallography has shown that conformation of the active site is indeed 
altered in mutant SOD (Deng et al., 1993). Durham et al., (1997), have shown 
that over-expression of mutant, (but not wt), S0D1 in primary neuronal cell 
cultures leads to inclusion formation and cell death, and SODI-positive 
inclusions are frequently found เท ALS patient spinal cord samples and mouse 
models of ALS (Shibata et al., 1996, Bruijn et al., 1998, respectively). 
Chaperone proteins, present in all cells and organelles, function to 
support the correct folding of proteins. Therefore, chaperones may be a key 
factor in the ability of cells to protect themselves against the aggregation of 
mutant S 0 D 1 . Chaperone proteins have been shown to be up-regulated in cells 
and tissues containing mutant, but not wt, S0D1 (Bruening et al., 1999). 
However, this up-regulation, was not observed in the spinal cord of mutant 
S0D1 transgenic mice, leading Brueining et al., (1999), to propose that mutant, 
mis-folded SODI present within a cell may divert the chaperone proteins 
towards trying to re-fold it and thus away from the re-folding of other proteins. 
This process may have detrimental affects on the cell, leading to aggregation of 
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other proteins, thereby rendering the cell more susceptible to other 
environmental and physiological stresses and ultimately leading to dysfunction 
and death. Most cells are able to up-regulate chaperones but it is possible that 
MNs are deficient in their ability to do this. A report by Batulan et al., (2003)， 
investigated the heat shock response เท MNs and showed that these cells have 
a high threshold for this response, due to lack of activation of HSF 1. In 
stressed cells, containing insufficient levels of HSPs, HSF1 trimerises and binds 
HSEs. Multiple phosphorylation then causes conformational changes, finally 
resulting in the recruitment of transcription machinery and transcription of heat 
shock protein genes (Morimoto and Santoro, 1998). The deficiency of MNs in 
their ability to initiate the heat shock response may render them selectively 
vulnerable in ALS. Bruening et al., (1999) tested this hypothesis by co-injecting 
HSP 70 and mutant S0D1 into cultured primary MNs. This led to a decrease in 
the number of cells containing mutant S0D1 inclusions and prolonged cell 
survival. 
Mutant S0D1 from NIH3T3 cell extracts and G93A mutant S0D1 
transgenic mice spinal cord extract is detergent insoluble, and chaperone 
proteins, namely HSPs 70， 40 and aB-crystallin, co-immunoprecipitate with 
mutant S0D1 from NIH3T3 cells (Shinder et al., 2001). studies using the Neuro 
2a cell line have shown that mutant, but not wt, S0D1 induces inclusion 
formation, fewer neuntes and cell death (Takeuchi et al., 2002). Over­
expression of HSPs 70 and 40 suppresses this aggregation of mutant S0D1 ， 
promotes neu rite outgrowth and suppresses cell death in these Neuro 2a cells 
(Takeuchi et al., 2002). Thus far, these studies, demonstrating the beneficial 
role of HSPs in mutant S0D1 inclusion formation have been carried out in cell 
models in vitro. A more recent report, however, showed that up-regulation of 
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HSPs in a mouse model of ALS increased the life expectancy of these animals 
(Kieran et al., 2004). This up-regulation of HSPs was induced by the 
administration of the drug arimoclomol to G93A mutant S0D1 transgenic mice, 
and led to improved muscle function and increased MN survival, resulting in a 
22% increase in lifespan. Arimoclomol is a hydroxylamine derivative which acts 
as a co-inducer of HSP expression by prolonging activation of HSF1 (Hargitai et 
al., 2003). Kieran et al., (2004), showed that in the G93A mutant SODI 
transgenic mice, arimoclomol acts, through HSF1 ， to up-regulate HSP 90 and 
70. HSP 27 was not up-regulated in response to arimoclomol, but the up-
regulation of other sHSPs, such as aB-ctystallin, was not studied. The 
mechanism by which this up-regulation of HSPs leads to an increase in life 
expectancy in these mice was not addressed in this study. Thus it is not known 
whether HSP 90 and 70 are capable of ameliorating the effects of mutant SODI 
inclusions in this in vivo system. In light of the presence of mutant S0D1 
inclusions in animal models (Bruijn et al., 1998) and patients (Shibata et al., 
1996), and evidence that HSPs decrease mutant S0D1 inclusion formation in 
cell systems (Buening et al., 1999, Takeuchi et al., 2002), it is likely that this is 
indeed the case, although it is possible that they are exerting their effects in 
other ways. However a recent report has demonstrated that increasing HSP 70 
in mutant S0D1 transgenic mice gave no protection against disease 
pathogenesis (มน et al., 2005). 
This protective role of HSPs extends to other neurodegenerative 
diseases. Using Drosophila melanogaster as a model of polyglutamine disease, 
Warrick et al., (1999), showed that the directed expression of HSP 70 
suppressed polyglutamine mediated neurodegeneration. Over-expression of 
HSPs 70 and 40 reduced aggregate formation and suppressed apoptosis in a 
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neuronal cell model of SBMA (Kobayashi et al., 2000). SCA1 is another 
example of a polyglutamine disease. High levels of HSP 70 in SCA1 transgenic 
mice were shown to suppress neuropathology and improve motor function 
(Cummings et al., 2001). 
From the data reviewed above, it can be concluded that chaperone 
proteins play an important role in protein aggregation during the process of 
neurodegeneration. Furthermore, mutations in HSPs have recently been linked 
to neurodegenerative diseases (Irobi et al., 2004 and Evgrafov et al., 2004), 
further supporting this role. The work presented in this study has focussed on 
investigating the role of sHSPs in the process of mutant S0D1 inclusion 
formation. 
In order to study this, it was first necessary to establish a model system 
in which these investigations could be carried out. HEK293 cells displayed good 
transfection rates and it was possible to induce mutant S0D1 inclusion in these 
cells, as shown by IMF microscopy (see chapter 3, mutant S0D1 inclusion 
formation in culture cells). Over-expression of wt YFP-tagged S0D1 เท HEK293 
cells did not lead to inclusion formation, either in the presence or absence of 
proteasome inhibitor. Over-expression of YFP-tagged mutant SOD 1s in 
HEK293 cells lead to inclusion formation in the presence, but not the absence, 
of proteasome inhibitor. This over-expression of mutant SODI in HEK293 cells 
and subsequent treatment with the proteasome inhibitor ALLN provides a model 
cell system of mutant S0D1 inclusion formation which could be used for further 
studies. Over-expression of YFP-tagged mutant S0D1 was also carried out 
using other cell lines available in the laboratory, (namely mH36, MCF7 and 
บ373), and during these studies it was noticed that endogenous levels of 
sHSPs affected mutant S0Đ1 inclusion levels. MCF7 and บ373 cells, which 
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have higher levels of aB-crystallin and HSP 27， have lower numbers of 
inclusions compared to mH36 and HEK293 cells, which have lower levels of 
these proteins. These findings support previous reports, which showed that 
experimentally increasing the level of chaperone proteins resulted in a decrease 
in the number of mutant S0D1 inclusions (Brueining et al., 1999， Takeuchi et 
al., 2002). Bruening et al., (1999) demonstrated that increasing HSP 70 levels 
decreased mutant SODI inclusions and prolonged survival in cultured primary 
MNS, and Takeuchi et al., (2002), reported similar findings following the over-
expression of HSP 70 and 40 in Neuro 2a cells. 
Having established this model cell system of mutant S0D1 inclusion 
formation, cell staining and IMF microscopy were carried out and used to show 
that chaperone proteins and components of the UPS co-localised to these 
inclusions. This result was in fact expected; Shinder et al., (2001), showed, 
using IP studies, that mutant SODI interacts with aB-crystallin, HSP 40 and 70 
in NIH 3T3 cells, and Bruijn et al., (1998), showed in FALS patients and mouse 
models of the disease, that mutant S0D1 inclusions contain ubiquitin. Dorfin 
(an E3 ligase) expression has also been shown to be elevated in the spinal cord 
of ALS patients (Ishigaki et al., 2002) and is present in inclusions in both FALS 
and SALS (Niwa et al., 2002). Over-expression of dorfin has been shown to 
prevent cell death induced by mutant protein, presumably by promoting its 
degradation via the UPS (Niwa et al., 2002). 
Ubiquitin containing inclusions have frequently been observed in many 
neurodegenerative diseases. The UPS constitutes the protein degradation 
machinery of the cell and is responsible for the removal of mis-folded proteins 
tagged with Ub. The presence of Ub containing inclusions within a cell is 
probably related to a deficiency in the UPS and, consequently its inability to 
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remove mis-folded proteins. Protein aggregates can inhibit the UPS (Bence et 
al., 2001), but this creates a positive feedback loop, as protein aggregates are 
also the products of UPS inhibition. Is it possible, therefore, that this feedback 
mechanism may have a role in the loss of neuronal function which characterises 
the progression of many of these neurodegenerative diseases? At present, this 
remains unanswered. บrushitani et al., (2002), have shown that the presence of 
mutant mis-folded S0D1 reduces the catalytic activity of the UPS in a 
neuroblastoma cell line. Furthermore, this is not due to incorporation of 
proteasome components into inclusions, as occurs in some other 
neurodegenerative diseases (Cummings et al., 1998). บrushitani et al., (2002), 
also proposed a model of disease pathogenesis in ALS: mutant, mis-folded and 
polyubiquitinated S0D1 overloads the UPS, leading to its further accumulation. 
Such accumulation will have an affect on the normal functioning of S0D1 i.e. it 
will cause impairment of the defence mechanisms that protect against stress. 
As a consequence of this, the increased stress may cause further mis-folding of 
proteins, including mutant S0D1 , thereby exacerbating the substrate overload 
on the UPS even further. All this results in a self-perpetuating cycle occurring 
within the cell. 
It is of interest that in both cell types used in this study, over-expression 
of mutant S0D1 alone was not sufficient to induce inclusion formation. In both 
HEK293 and N2a cells (used in later experiments), the addition of proteasome 
inhibitor was also required in order to induce inclusion formation. This suggests 
that the cells may be subject to multiple stresses before mutant SODI inclusion 
formation can occur. Is there a similar occurrence in ALS patients? If so this 
could go some way to explain the selective degeneration of MNs during disease 
progression. SODI is ubiquitously expressed throughouMhe nervous system, 
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and indeed the body, and the question as to why MNs are selectively vulnerable 
is central to the understanding of ALS disease pathogenesis. If mutant SODI 
alone is insufficient to form inclusions, and a combination of other stresses is 
also required, it could be the case that MNs, compared to other cell types, are 
more susceptible to these other stresses, e.g. physiological or oxidative stress. 
Evidence to support this includes the demonstration that MNs have a high 
threshold for the activation of the heat shock response, due to lack of activation 
of HSF1 (BatuIan et al., 2003). Also, due to their role in relaying electrical 
impulses and effecting muscle movement, MNs are continually subjected to the 
physiological stress of a high excitatory input. 
In other neurodegenerative diseases, mutant protein has been shown to 
affect transcription, which in turn may contribute to neurodegeneration. 
Huntingtin is the protein which causes Huntington's disease when its 
polyglutamine tract is extended above thirty-seven polyglutamie residues. 
Truncated N-terminal mutant Huntingtin represses transcription, whereas wt 
huntingtin does not (Kegel et al., 2002). In Alzheimer's disease, a 
phosphorylated, C-terminal fragment of APP, the precursor of plaque forming 
amyloid protein, is present in the nucleus and localises to the splicing factor 
compartment (Muresan and Muresan, 2004). This indicates that APP may have 
a role in pre-mRNA splicing and/or transcription in this disease. We investigated 
the possibility as to whether mutant S0D1 could contribute to ALS disease 
progression in a similar way by affecting transcription. Speckles, or 
interchromatin granules, are distinct nuclear structures involved in the 
processing and transcription of RNA (Wei et al., 1999). They can be detected 
using antibodies to components of the spliceosome, either snRNP components 
Є;д. Sm and UIA, or non-snRNP components e.g. SG35 and TMG (Antóniou et 
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al., 1993). By looking at the pattern of speckles obtained with such antibodies, 
insights into the transcriptional activity of the cell can be gleaned. Using such 
antibodies, we showed that mutant S0D1 did not affect transcription in our 
HEK293 system of mutant S0D1 inclusion formation, as no difference in 
speckle pattern was observed in cells expressing wt or mutant S0D1 (Figure 
3.6). This suggests that alterations in transcription by mutant S0D1 do not have 
a role in the disease pathogenesis of ALS. 
Biochemical analysis of cell extracts from HEK293 cells containing 
mutant S0D1 inclusions showed that 22.4% of the mutant S0D1 was insoluble. 
Over-expression of aB-crystallin and HSP 27 under these conditions decreased 
the proportion of insoluble S0D1 from 22.4% to 0% for aB-crystallin and 4.4% 
for HSP 27 (see chapter 4， effects of sHSPs on insoluble G85R S0D1 levels in 
HEK293 cells). Although the question as to whether inclusions are either 
directly toxic, or act as a protective sink mechanism remains controversial; 
these data support the findings of an earlier report (Kieran et al., 2004), which 
showed that a co-inducer of HSPs improved disease pathogenesis in mutant 
S0D1 mice. When mutant forms of these sHSPs were over-expressed under 
these conditions, the proportion of insoluble mutant SODI was further 
increased, to 31.8% for R120G aB-crystallin and 30.9% and 37.3% for ร135F 
and R140G HSP 27， respectively (see chapter 4, mutant sHSPs: are they 
involved in ALS?). These mutations result in the proteins being unable to fold 
correctly and thus indirectly lead to their dysfunction (Bova et al., 1999, Perng et 
al., 1999b, Chavez Zobel et al., 2003). Bruening et al., (1999), showed that 
over-expression of HSP 70 prevented mutant S0D1 inclusion formation and 
subsequent cell death in cultured primary MNs. Furthermore, Takeuchi et al., 
(2002), showed that over-expression of HSP 40 and 70 in N2a cells which 
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contained mutant S0D1 inclusions, suppressed the aggregation of mutant 
S0D1 , promoted neu rite outgrowth and prolonged cell survival. All these data, 
together with that presented by к๒ran et al., (2004), would support a protective 
role for HSPs. Similar findings have been reported in other neurodegenerative 
diseases. Over-expression of HSP 70 has been shown to suppress 
polyglutamine mediated neurodegeneration, (Warrick et al., 1999), 
neuropathology in SCA1 mice (Cummings et al., 2001) and decreased inclusion 
formation and suppressed apoptosis in a cell model of SBMA (Kobayashi et al., 
2002) . However, this assumes that inclusions are toxic. As previously 
mentioned, there are still contradicting views as to whether inclusions are toxic, 
or whether they act as a 'sink' for toxic soluble proteins. This subject has been 
reviewed by Tran and Miller (1999). Reports by Bruening et al., (1999) and 
Takeuchi et al., (2002), showed that mutant S0D1 inclusion formation results in 
cell death. In this study cell viability assays were carried out on HEK293 cells 
containing mutant S0D1 inclusions in the presence and absence of wt and 
mutant sHSPs. Although over-expression of mutant S0D1 alone did not result 
in any adverse effects, the addition of proteasome inhibitor, to induce inclusion 
formation, resulted in a significant increase เท cell death. This suggests that 
additional stresses are detrimental to cells which already express mutant S 0 D 1 . 
As MNs are already compromised in their stress response (Batulan et al., 
2003) , it is easy to see how expression of mutant S0D1 in these cells could 
lead to cell dysfunction and death. Under these conditions over-expression of 
either wt or mutant sHSPs, did not significantly affect cell viability, despite their 
effects on the proportions of insoluble mutant SODI . As with all the other 
experiments presented here, these viability studies were carried out twenty-four 
hr following transfection. It might be the case that after prolonged exposure to 
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the inclusions, additional effects would have become apparent. Although these 
data show that aB-crystallin and HSP 27 both interact with mutant S0D1 in 
vivo, and in doing so alter the proportions of insoluble material, this interaction 
may not be a direct one. The interaction of both wt and mutant S0D1 with aB-
crystallin was studied in vitro. Although three different methods were used, 
namely IP, SEC and Biacore, none of these demonstrated an interaction 
between the two proteins (see chapter 5). This is somewhat unexpected: (a) 
due to our in vivo results described above, and (b) due to the results from 
Shinder et al,, (2001), where it was demonstrated that HSP 70, 40 and aB-
crystallin co-immunoprecipitated with mutant S0D1 from NIH-3T3 cells. From 
our results alone, it would be easy to argue that the mutant SOD-sHSP 
interaction is not a direct one, but one which involves other proteins in vivo 
which are not present in the in vitro assays. However, the data presented by 
Shinder et al., (2001), does not support this. Maybe our three chosen methods 
are not best suited to the studies carried out. They were selected due to 
departmental availability, but it is possible that there are other methods which 
would have been better suited, for example Far Western Blotting or yeast two-
hybrid analysis. Unfortunately, for the IP experiments, the protein-G coupled 
beads themselves interacted with the S 0 D 1 . If this problem had been 
overcome, maybe a true interaction could have been demonstrated. It is also 
possible that aggregated S0D1 interacts with aB-crystallin; soluble S0D1 was 
utilised in the experiments described here. 
When wt S0D1 was over-expressed in the HEK293 cell system, even in 
the presence of proteasome inhibitor, it remained soluble, as shown by IMF 
mieroseopy and biochemical analysis. However, when mutant aB-crystallin and 
mutant HSP 27 were over-expressed together with wt S0D1 , followed by 
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treatment with proteasome inhibitor, some of the normally soluble S0D1 was 
shifted into the insoluble fraction. Mutations in sHSPs have recently been linked 
to neurodegenerative diseases. Mutations in HSP 27 have been linked to CMT 
disease and distal hereditary motor neuropathy (Evgrafov et al., 2004) and 
mutations in HSP 22 have been identified in families with distal hereditary motor 
neuropathies (Irobi et al., 2004). Is it possible that sHSPs are also mutated in 
ALS and contribute to protein aggregation? What about the vast majority of ALS 
cases that are not linked to mutations in S0D1? Are mutations in chaperone 
proteins seen here? Mutations in sHSPs result in their being unable to fold 
correctly, consequently rendering them prone to aggregation and affecting their 
activity (Bova et al., 1999, Perng et al., 1999b, Chavez Zobel et al., 2003). If, 
through some as yet unidentified interaction, they are able to sequester 
proteins, which are normally soluble, into inclusions, as has been observed in 
these studies for mutant S0D1 , this may have deleterious effects on the cells, 
thus making them more susceptible to other stresses. S0D1 is involved in 
protecting cells from oxidative stress, so decreasing the amount of available 
S0D1 would lead to an increase in superoxide radicals which could damage 
cellular macromoleculeร. Again, these findings could hint at the selective 
vulnerability of MNs in ALS, as MNs are subject to a high excitatory input 
compared to other cell types. Thus, MNs may be particularly sensitive to 
increased levels of oxidative stress. 
The results obtained from the HEK293 cell system showed that over-
expression of sHSPs decreased the proportion of insoluble mutant SODI . Do 
sHSPs have similar effects in N2a cells? Compared to the HEK293 cell model, 
a neuronal cell line could provide a model system better suited to studying ALS. 
It was shown that over-expression of YFP-tagged G85R mutant S0D1 and 
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subsequent treatment with proteasome inhibitor induced S0D1 inclusions in 
N2a cells. However, as the transfection rate was low in this cell line it was not 
possible to quantify the proportion of insoluble mutant S0D1 , as was the case 
in the HEK293 cell system. Over-expression of sHSPs affected the physical 
appearance of the mutant S0D1 inclusions. Instead of dense inclusions 
observed when mutant S0D1 alone is expressed, the presence of aB-ctystallin 
and HSP 27 resulted in the inclusions being more diffuse in phenotype. Similar 
findings have been reported by Takeuchi et al., (2002). They showed that over-
expression of HSPs 70 and 40 in Neuro 2a cells resulted in a change in the 
appearance of inclusions to a more diffuse pattern throughout the cytoplasm. 
The results from the HEK293 cell system support these findings for a role of 
sHSPs in mutant S0D1 inclusion formation. To obtain more definite conclusions 
about this possible role, it would be of use to study the effects of sHSPs on 
mutant S0D1 inclusion formation in another neuronal cell line which would be 
easier to transfect and better suited to IMF microscopy studies. 
It has been shown here that over-expression of sHSPs in a model cell 
system of mutant S0D1 inclusion formation decreases the proportion of 
insoluble mutant S0D1 (see chapter 4) It is likely that decreasing the insolubility 
of mutant S0D1, as determined biochemically, coincides with a decrease in 
mutant S0D1 inclusions, although we have not been able to demonstrate this 
directly, due to treated HEK293 cells becoming detached from the slides during 
processing for IMF microscopy. This supports numerous other reports 
(Bruening et al., 1999, Warrick et al., 1999, Kieran et al., 2004), which show that 
up-regulation of HSPs are beneficial both in cell and animal models for a range 
of neurodegenerative diseases. But how exactly is this up-regulation of HSPs 
beneficial? They decrease the amount ๙ insoluble mutant ร Θ Ρ Ι and the 
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numbers of mutant S0D1 inclusions, but how is this achieved? This has not 
been addressed here, studies in NIH3T3 cells (Shinder et al., 2001) showed 
that mutant S0D1 co-immunoprecipitates with HSP 70, 40 and aB-crystallin, 
suggesting that HSPs interact directly with the mutant S 0 D 1 . Results from our 
in vitro studies however, do not support these findings (discussed previously). 
Another question is whether HSPs and sHSPs act co-operatively in their roles 
to decrease mutant S 0 D 1 . Most of the studies to date which have implicated a 
role for chaperone proteins in mutant S0D1 inclusion formation in ALS 
(Bruening et al., 1999， Takeuchi et al., 2002, Kierän et al., 2004), have shown 
that it is an increase in HSPs which decrease mutant S0D1 inclusions. The 
results presented here show a similar role for sHSPs. Does raising the capacity 
of one component of a cells chaperone machinery lead to increases in levels of 
others? All HSPs are up-regulated in response to stress (Morimoto et al., 1997), 
but whether over-expression of one HSP in cell and animal systems leads to 
increases in others has not been directly addressed. A report by Lee et al., 
(1997), proposed that energy-independent sHSPs trap non-native proteins 
during stress conditions, thus protecting them from aggregation. Under 
permissive conditions, energy-dependent chaperones can then complete the 
refolding of this reservoir of folding-competent protein. Thus, sHSPs prevent 
rapid protein aggregation by initiation of binding events while other chaperones 
primarily refold non-native protein. This suggests that both sHSPs and HSPs 
would be required to decrease mutant S0D1 inclusions within cells, so maybe 
HSPs do act co-operatively and that an increase in one chaperone component 
leads to increases in other chaperone components. 
Whether these effects of HSPs will be of any therapeutic benefit remains 
to be determined. However, it must be remembered that the over-expression of 
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mutant SODI in these animals is much greater than is seen in ALS patients. 
Although such animals provide a good model for ALS and allow important 
insights into disease mechanisms, this must be taken into account when 
considering these systems. 
It has also been shown that over-expression of mutant, inactive sHSPs 
results in an increase in the insolubility of normally soluble proteins. Two recent 
reports have linked mutations in sHSPs to related neurodegenerative diseases 
(Irobi et al., 2004, Evgrafov et al., 2004). It is possible that such mutations may 
contribute to disease pathogenesis in the majority of those ALS cases not linked 
to mutant S0D1 . This is potentially an interesting area of new research, which 
warrants further investigation. 
The results presented here are based around mutant S0D1 ， which can 
mis-fold and form inclusions. Ten percent of ALS cases are inherited (FALS 
cases), and of these, only 20% are linked to mutant S 0 D 1 . What is happening 
in the 90% of non-inherited ALS cases? Can the findings presented here help 
us to understand the pathogenesis of these sporadic cases? It is possible, of 
course, that S0D1 is mutated in some of these non-inherited cases, but there 
are other factors which have been shown to contribute to ALS disease 
pathogenesis. The accumulation and abnormal assembly of NFS are a hallmark 
of ALS (Carpenter, 1968), and mutations in NFs have been shown to result in 
degeneration of MNs (Xu et al., 1993, Cote et al., 1993). Excitotoxicity has been 
shown to contribute to ALS and increased glutamate in cerebrospinal fluid from 
ALS patients has been reported (Rothstein et al., 1990, Rothstein et âl., 1991, 
Shaw et al., 1995). Loss of the astroglial glutamate transported EAAT2 has 
been shown to be responsible for abnormal glutamate transport (Rothstein et 
al., 1995). Other factors implicated in this disease include mitochondrial defects 
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such as vacuolation, which can be detected early in disease progression (Kong 
and Xu， 1998), activation of apoptosis (Martin 1999, Pedersen et al., 2000) and 
reduced VEGF expression (Lambrechts et al., 2003). 
Can the results obtained here help us to understand these mechanisms 
and how they lead to MN degeneration? Our experiments were designed to 
address aggregation of mutant SODI and the results show that increased levels 
of sHSPs decrease the insolubility of ทานtant SOD 1. These other contributing 
factors in ALS described above are not known to involve protein aggregation, so 
whether increased levels of sHSPs will be beneficial in these cases is not clear. 
One role of HSPs is in stabilising the cytoskeleton (Perng et al., 1999a), so their 
up-regulation may be beneficial in the case of NF disruption, but this is unlikely 
as currently there are no reports demonstrating that they are themselves 
involved in this disruption, other reported roles of sHSPs include inhibition of 
apoptosis (Bruey et al., 2000, Kamradt et al., 2001, Mehlen et al., 1996). As 
activation of apoptosis has been reported in ALS patients (Martin 1999, 
Pedersen et al., 2000) and may contribute to disease pathogenesis, it is 
therefore possible that in these cases, the up-regulation of sHSPs can confer 
some protection against apoptosis and its possible contribution to disease 
progression. In the case of glutamate-mediated excitotoxicity, there is a link 
between FALS and SALS. Howland et al., (2002), have reported that decreased 
levels of EAAT2 are observed in a rat model of ALS and Trotti et al,, (1999), 
showed that mutant, but not wt, S0D1 inactivates EAAT2. If mutant SODI 
mediates this inactivation through inclusion related mechanisms, up-regulation 
of sHSPs may help to prevent this inactivation of EAAT2. 
A recent report by Clement et al., (2003), suggested that mutant S0D1 
mediated toxicity is non-cell autonomous. Using chimeric mice, they 
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demonstrated that mutant S0D1 , acting within non-neuronal cells, is required เท 
order to cause damage to MNs, and that non-neuronal cells, which do not 
express mutant S 0 D 1 , improve survival of mutant S0D1 expressing MNs. The 
mechanisms by which normally functioning non-neuronal cells could prevent 
degeneration in neighbouring MNs is presently unknown. The results presented 
by Clement et al., (2003), support a body of evidence, discussed previously, 
which suggests that up-regulation of chaperone proteins helps to reduce mutant 
S0D1 inclusion formation and improve survival in various cell models and in 
G93A mutant S0D1 transgenic mice. There is speculation that MNs may be 
deficient in their ability to up-regulate chaperone proteins (BatuIan et al., 2003), 
and that this may be key to their selective dysfunction and degeneration in ALS. 
However, the fact that mutant SODI inclusions in MNs alone per se do not 
cause dysfunction and death (Clement et al., 2003), suggests that the heat 
shock response in MNs is not a problem. Maybe the other non-neuronal cells 
which contribute to MN dysfunction and death have deficiencies in their heat 
shock response and expression and accumulation of mutant SOD1 within these 
cells leads to detrimental effects on surrounding cells including MNs. 
The surrounding non-neuronal cells support MNs; for example, 
astrocytes provide MNs with nutrients and neurotrophic factors, as well as 
scavenging neurotransmitters, such as glutamate (Oppenheim et al., 1988, Lin 
et al., 1993). It is possible that the presence of mutant S0D1 inclusions within 
these non-neuronal cells affects their ability to carry out these support functions 
efficiently. It is not known exactly how inclusions exert their affects, but 
hypotheses include co-aggregation with other proteins, resulting in the cells 
being depleted of essential components, burdening of the UPS, disruption of 
axonal transport and induction of apoptosis. Such events in these cells may 
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impair their ability to efficiently support the surrounding MNs, leading to their 
degeneration and death. As we have demonstrated here, increasing HSP 
protein levels decreases the amount of insoluble mutant S 0 D 1 . How is this 
relevant in relation to the results presented by Clement et al., (2003)? Findings 
similar to ours have been reported in a mouse model of ALS (Kierän et al., 
2004). Increasing HSP levels in G93A mutant S0D1 transgenic mice leads to 
increased MN survival and prolongs life expectancy in these animals (Kieran et 
al., 2004). Maybe the HSPs decrease mutant S0D1 inclusions present within 
non-neuronal cells, allowing them to function more efficiently in their role of 
providing MNs with nutrients and growth factors, thus improving MN survival 
and prolonging life expectancy. Clearance of mutant S0D1 from surrounding 
non-neuronal cells may improve their functioning and consequently their ability 
to support MNs, thereby helping to prevent their degeneration and death. 
In conclusion, the results of this study show that increases in sHSPs can 
help prevent mutant S0D1 inclusion formation in a model cell system. This 
supports other evidence for beneficial roles of chapenวnes in mutant S0D1 
inclusion formation in cell and animal models of ALS. How this relates to the 
vast majority of non-SOD1 linked ALS cases is not clear. If these cases involve 
protein aggregation, then increases in sHSPs are likely to be beneficial, as they 
are not specific for mutant S 0 D 1 . Also, it has been shown that mutant sHSPs 
cause increased insolubility of mutant S 0 D 1 . Mutations in sHSPs in related 
neurodegenerative diseases were reported last year (Irobi et al., 2004, Evgrafov 
et al., 2004). It is possible that mutant sHSPs contribute to ALS in the non-
S0D1 linked cases, by increasing the insolubility of proteins which, under 
normal cellular conditions are soluble. ALS is a disease in which multiple factors 
and pathways have been shown to contribute to disease pathogenesis. 
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Increasing levels of chaperones proteins may be of therapeutic benefit in cases 
that involve protein aggregation and inclusion formation but a lot more research 
is needed to better understand the mechanisms which underlie the 
degeneration of MNs in ALS, such that therapeutic strategies can be designed 
to treat and prevent this debilitating disease. 
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